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Colon cancer and obesity are two significant and related pathological states with multiple etiological 
factors. In this dissertation, it was hypothesized that tumor growth is accelerated in the altered state of 
obesity due to their resistance towards tumor necrosis factor-α (TNF-α) mediated cytotoxicity. 
Physiologically elevated TNF-α in an obese state induces increased nuclear transcription factor-κB 
(NF-κB) activity, known to transcribe genes crucial to cell survival. Insulin resistance, oxidative 
stress, and a pro-inflammatory environment are few of the biological consequences of TNF-α and 
NF-κB pathway activation, and further contribute to disease progression.  
 
Three major studies were conducted to investigate phenotypical changes in obesity associated tumors. 
Firstly, characteristics of the TNF-α resistant phenotype were preliminarily assessed by evaluating the 
effects of exogenous TNF-α treatment to HT-29 cells. Elevated levels of NF-κB in response to 
exogenous TNF-α gave an indication that this pathway is critical for cell survival. Furthermore, 
upregulation of TNF-α receptor 2 (TNFR2) suggested another strategy by which the cells were 
utilizing exogenous TNF-α for a survival advantage. Inhibition of NF-κB via St. John’s Wort 
treatment demonstrated that HT-29 cells may be sensitized towards TNF-α mediated cytotoxicity.  
 
Zucker obese (Zk-Ob), Zucker lean (Zk-Ln), and Sprague Dawley (SD) animal models were used to 
assess tumor phenotype in vivo. Remarkable physiological differences between genotypes were 
observed. Zk-Ob rats had significantly higher body and organ weights as well as plasma TNF-α, 
insulin, leptin, and oxidative markers than Zk-Ln and SD animals. Tumor incidence and multiplicity 
were also notably higher in Zk-Ob rats. Protein analyses demonstrated increased levels of TNF-α, 
TNFR2, NF-κB, IκB kinase β (IKKβ), insulin receptor (IR), insulin like growth factor-I-receptor 
(IGF-IR), and mitogen activated protein kinase (MAPK) in Zk-Ob tumors than Zk-Ln counterparts. In 
all groups, tumors generally had higher protein expression than surrounding, normal appearing 
colonic mucosa. It is well known that these molecules are involved in signaling pathways that 
influence and co-operate with each other in rendering growth autonomy to tumor tissue.  
 
A higher number of lesions in the distal than proximal colon in Zk-Ob rats was observed, supporting 
the emerging concept that genotype/physiological state of the host affects development and 
distribution of tumors. Thus, a third study was conducted to explore differences between distal and 
 
 iv 
proximal tumor phenotype. Results demonstrated that expression of TNFR2, NF-κB, IR, IGF-IR, and 
MAPK p44 were significantly higher in distal than proximal tumors. This observation suggested that 
development of tumors in different regions of the colon varied under the same physiological 
conditions. Moreover, phenotype of distal tumors appeared to be upregulating survival pathways in 
comparison to proximal lesions, possibly explaining the higher tumor incidence in the distal colon.   
 
Research documented in this thesis supported the hypothesis that the physiological status of the host 
intricately affects tumor phenotype. In particular, the TNF-α resistant phenotype was most prominent 
in Zk-Ob tumors, and appeared to be associated with upregulation of multiple signaling pathways 
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Cancer and obesity are two significant causes of mortality considerably impacted by genetic and 
environmental etiological factors. While the epidemiological association between these two 
pathological states is well established, biochemical and molecular links are under review. Both are 
multi-factorial diseases with many contributing and interactive variables, making it difficult to isolate 
one particular causal mechanism. In this thesis project, TNF-α and NF-κB pathways were focused on 
due to their central roles in the manifestation of colon carcinogenesis and obesity.  
It was hypothesized that tumors are accelerated in the altered state of obesity associated colon cancer 
due to their resistance towards TNF-α mediated cytotoxicity. Furthermore, physiologically elevated 
TNF-α induces increased expression of transcriptionally active NF-κB, known to transcribe genes 
crucial to cell survival. A pro-inflammatory environment, oxidative stress, and insulin resistance are 
few of the biological consequences of TNF-α and NF-κB pathway activation, and further contribute 
to disease progression. Three major studies were conducted to investigate this hypothesis, and their 
objectives and specific aims are described as follows. 
 
Study 1: Effects of TNF-α and NF-κB inhibitors on HT-29 colon cancer cells  
 
HT-29 colon adenocarcinoma cells were used as a preliminary approach to understand cellular and 
molecular changes associated with the TNF-α resistance phenotype. Specific aims of this study were: 
 
• To determine changes at protein levels of TNFR1, TNFR2, NF-κB, IκBα, and IKKβ in     
HT-29 cells treated to exogenous TNF-α.  
• To assess whether inhibition of NF-κB via St. John’s Wort extracts and standards augment 









Study 2: Tumor incidence and phenotype in Zk-Ob, Zk-Ln, and SD rats 
 
The second study utilized Zucker-obese (Zk-Ob) rats, an ideal model system for investigating obesity 
associated colon cancer, due to their inherent characteristics of elevated TNF-α levels and metabolic 
dysregulation. In addition, lean counterparts, Zucker-lean (Zk-Ln) rats, and Sprague dawley (SD) rats 
functioned as control groups.  
 
The primary objective of this study was to determine if tumors appearing in Zk-Ob rats are 
biologically different from those in Zk-Ln and SD rats. It was hypothesized that the physiological 
state of Zk-Ob rats would affect tumor phenotype. In particular, elevated levels of TNF-α in these 
animals would exert a tumor promoting effect by inducing increased expression of transcriptionally 
active NF-κB, known to transcribe genes important for cell survival.  
 
In order to accomplish this objective, this study was divided into three components with the following 
aims:  
 
Study 2A: Assessment of physiological, hematological, and biochemical parameters in Zk-Ob, 
Zk-Ln, and SD rats 
 
Specific aims of this study were to determine effects of genotypes of Zk-Ob, Zk-Ln, and SD rats on:  
• Body and organ weights 
• Complete blood count 
• Plasma levels of TG, HDL, cholesterol, glucose, insulin, leptin, TNF-α, sTNFR1, and 
sTNFR2 
• Plasma levels of oxidative stress markers 
 
Study 2B: Assessment of tumor parameters in Zk-Ob, Zk-Ln, and SD rats  
Specific aim of this study was to determine effects of genotypes of Zk-Ob, Zk-Ln, and SD rats on: 




Study 2C: Assessment of protein expression patterns in tumors and colonic mucosa of Zk-Ob, 
Zk-Ln, and SD rats 
Specific aims of this study were to determine effects of genotypes of Zk-Ob, Zk-Ln, and SD animals 
on tumor and colonic mucosal protein expression of the following: 
• TNF-α, TNFR1, and TNFR2 
• NF-κB, IκBα, and IKKβ 
• IRα, IRβ, and IGF-IRα 
• MAPK p42/p44 
 
Study 3: Differences in protein expression patterns in distal and proximal tumors of 
Zk-Ob rats 
 
In study 2B, it was observed that the tumor distribution pattern along the colonic axis was different in 
Zk-Ob versus Zk-Ln and SD rats. To be specific, it was noted that the majority of tumors in Zk-Ob 
rats were located in the distal regions of the colon. This observation was in keeping with recent 
interests generated in the field of cancer biology that proximal and distal tumors represent 
biologically different disease states. An overall abundance of tumors in Zk-Ob rats allowed a more 
detailed comparison of tumor phenotype with regards to location along the colonic axis. 
Specific aim of this study was:  
      To determine if tumors in Zk-Ob rats present in the distal colon exhibit different phenotypes from    
      those in the proximal colon. In particular, expression of key proteins of the TNF-α, NF-κB, and   
      insulin pathways were investigated as identified below:  
• TNF-α, TNFR1, and TNFR2 
• NF-κB, IκBα, and IKKβ 
• IRα, IRβ, and IGF-IRα 






Colon Cancer  
1.1 Cancer 
The probability of an individual developing cancer in their lifetime lies between 30-50% (Park and 
Pezzuto 2002). One of the leading causes of mortality today, cancer is a general descriptive term for 
the abnormal growth of cells. Constantly working towards maintaining a homeostatic equilibrium, the 
body must also regulate a balance between cell death and proliferation. Disruption of this balance due 
to various causative factors often results in an altered response to growth control, potentially leading 
to cancer development.  
 
Numerous classes of genes such as proto-oncogenes, and mutated counterparts oncogenes, regulate 
cell division and apoptosis. Overexpression or dysregulation of these may initiate and promote 
carcinogenesis (Philip et al. 2004).  
 
The progression of cancer, carcinogenesis, is a multi-step process involving stages of initiation, 
promotion, and cell proliferation (Macarthur et al. 2004). Cells first undergo transformation upon 
which they exhibit altered growth properties and morphology due to genetic or environmental factors 
such as chemical carcinogens, irradiation, and bacterial or viral infections (Goldsby et al. 2003). 
Animal studies have demonstrated that transformed cells in culture are capable of inducing tumor 
formation when transplanted in vivo (Reddy 2004). Transformation itself has two stages, initiation 
and promotion, the latter of which leads to malignancy. Initiation involves changes in the cell genome 
and irreversible DNA damage affecting protein expression, and a decreased responsiveness to growth 
control mechanisms. On the other hand, promotion involves clonal selection and propagation of 
initiated cells 
 
Uncontrolled cell division often results in formation of neoplasms (new growth) which are 
characterized as a benign, or a non-invasive, non-indefinite type of growth. Conversely, malignant 
tumors are an invasive, indefinite growth that may metastasize to other regions of the body through 




1.2  Colon 
The large intestine, the terminal part of the gastro-intestinal tract, is a muscular tube about 1.5 meters 
in length. Specifically, the colon consists of the caecum (with an attached appendix), ascending, 
transverse, descending and sigmoid components, and ends with the rectum. Primary functions of the 
colon involve processing of waste material, reabsorption of water and nutrients, and mucous 
production (Moore and Dalley 1999).  
 
Histologically, the colon has four distinct layers of mucosa and muscle: mucosa, submucosa, 
muscularis externa and serosa (Figure 1-1) (Moore and Dalley 1999). The innermost mucosal layer 
consists of invaginations known as crypts lined with colonic epithelium. Unlike the small intestine, 
colonic crypts have no villi for nutrient absorption. Crypts are supported by the lamina propria 
consisting of connective tissue, blood vessels, and immune cells including lymphocytes and 
macrophages (Moore and Dalley 1999). This mucosal layer is the most common origin for colon 
cancers.  
 
Colonic epithelium is a highly diverse and dynamic system involving constant cell renewal (Ding et 
al. 1998). Continually proliferating stem cells situated at the base are responsible for replenishing the 
entire epithelium every 3-8 days (Cotran et al. 1999). This cell regeneration occurs within the base 
two-third portion of the crypt. As the cells migrate upwards they differentiate into specialized cell 
types including absorptive, mucous secreting, endocrine, and anti-bacterial protein secreting Paneth 






















Figure 1-1: Histology of the colon.    
The colon consists of layers of muscle and mucosa; mucosa, submucosa, muscularis externa and 
serosa. The inner most mucosal layer consists of invaginations known as crypts lined with colonic 

















Figure 1-2: Differentiation of colonic epithelium. 
Structure of a colonic crypt is displayed. Stem cells situated at the base of the crypt differentiate into 
specialized cell types found in mucosal layer, and regenerate the entire epithelium every 3-5 days 





1.2.1 Colon Carcinogenesis 
Colon cancer is the second leading cause of cancer-related deaths for both men and women in North 
America, and over 100 000 new cases are estimated for 2006 (Jemal et al. 2005). This accounts for 
11% of all cancers, and is preceded only by prostate, breast, and lung cancers. In addition, it is 
estimated that 50% of the population will develop an adenomatous polyp by the age of 70 (Jemal et 
al. 2005).  
 
Colon cancer has multiple etiological variables including diet, lifestyle, and contributing 
physiological disorders such as inflammation and obesity. Genetics also plays a role, and a common 
form of cancer known as familial adenomatous polyposis coli involves a mutation of the adenomatous 
polyposis coli (APC) gene (Cotran et al. 1991). Current treatment strategies of colon cancer include 
combinations of chemotherapy, radiation therapy, and surgery (Martinez 2005). 
 
A multi-step, multi-factorial process, colon carcinogenesis involves the clonal selection and 
propagation of initiated colonic epithelial cells, which progress from normal to precancerous to 
malignant states over a span of 5-40 years (Curtis 1991, Roncucci et al. 1991, Cheng and Lai 2003). 
The sequential events of colon carcinogenesis concerning genetic and phenotypical changes are very 
well characterized by the adenoma-carcinoma model first described by Fearon and Vogelstein (1990). 
In this model, inactivation of tumor-suppressor genes APC, DCC and p53, and activation of oncogene 
























Figure 1-3: Vogelstein model of colon carcinogenesis. 
Morphological changes in colonic epithelium may be correlated with genetic alterations during 
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1.2.2 Aberrant Crypt Foci 
Proliferation of initiated colonic cells leads to microscopic alterations to the normal histology of the 
colon, resulting in aberrant crypt foci (ACF) formation (Bird 1987). ACF, now well recognized as 
putative preneoplastic lesions, act as diagnostic biological markers for the process of colon 
carcinogenesis (Bird 1987).  
 
As these preneoplastic lesions develop, they acquire novel genotypic and phenotypic features 
(morphology and number of crypts) which correspond to their ability to develop, survive and combat 
negative growth signals. Evaluation of ACF number, crypt multiplicity, location, and growth 
properties are common characteristics used to assess disease status, and effects of potential 
preventative agents (McLellan et al. 1991). 
 
ACF have potential to undergo additional genetic alterations and progress into intra-epithelial benign 
structures known as polyps or adenomas, which may further advance to malignant lesions having the 
capacity to metastasize (Roncucci et al. 1991). 
 
1.4 Colon Cancer and Obesity 
Obesity is a premorbid condition and rising epidemic in North America, with both environmental and 
genetic etiological factors (Formiguera and Canton 2004). There is especially a well established 
epidemiological association between obesity and an increased risk for colon cancer (Rapp et al. 
2005). While the biochemical and molecular links between the two physiological disorders are still 
under review, the interconnected roles of insulin resistance, adipose tissue, and inflammation are 
































Figure 1-4: Pathogenic mechanisms linking obesity and colon cancer. 
Pathogenesis of obesity is attributed to multiple factors such as inflammation, insulin resistance, and 
constituents secreted by adipose tissue. The combination of these variables influence and augment 








Insulin resistance implies a cells inability to respond to normal levels of insulin, thus requiring 
abnormally high amounts of hormone for glucose metabolism. This condition further leads to 
irregular triglycerides, fatty acids and glucose levels, all metabolic aberrations that also correlate with 
an increased risk of colorectal cancer (Gunter and Leitzmann 2006). An emerging body of evidence 
emphasizes three possibilities that associate insulin resistance with colon cancer risk (reviewed in 
Gunter and Leitzmann 2006). Firstly, insulin itself is a growth factor, and exposure of high amounts 
to parts of the body that are otherwise not accustomed can interfere with normal cell signaling and 
promote cell proliferation. Insulin is observed to promote cell growth and proliferation in colon 
cancer cells (Gunter and Leitzmann 2006). Additionally, Kiunga et al. (2004) demonstrated elevated 
protein levels of insulin and insulin receptor in tumors compared to normal colonic mucosa.  
 
Secondly, an insulin resistant state also promotes high levels of circulating insulin-like growth factor 
(IGF), which can also promote colonocyte division and block apoptosis by receptor binding 
(Giovannucci 2001). Increased IGF-1-receptor (IGF-IR) also stimulates cell division in intestinal 
epithelial cells (Ma et al. 1999), and several epidemiological studies have shown positive correlation 
between IGF and IGF-IR levels and colon cancer risk (Komninou et al. 2003).  
 
Finally, the high circulating plasma glucose and lipids associated with insulin resistance serve as a 
reservoir for reactive oxygen species (ROS) generation, known contributors to carcinogenesis. High 
visceral abdominal fat found in obese individuals is especially a critical source for ROS (Furukawa et 
al. 2004, Frezza et al. 2005).  
 
Along with oxidative stress, increased amount of fat tissue promotes a pro-inflammatory 
environment, also strongly correlates with increased cancer risk. Cytokines/adipokines such as tumor 
necrosis factor-α are readily secreted by adiopcytes, and further enhance inflammation, insulin 
resistance, impaired glucose metabolism, and ROS production (Furukawa et al. 2004, Sonnenberg et 
al. 2004).  
 
Leptin, the hormone for satiety, has also been implicated in obesity associated colon cancer. Leptin 
has been shown to increase proliferation of HT-29 cells, and promote ACF formation in vivo (Liu et 
al. 2001). Conversely, F344 rats administered continuous leptin injections had reduced number of 
ACF in comparison to the controls (Aparicio et al. 2004). Leptin secreted from adipose tissue has also 
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been shown to enhance insulin resistance (Matsuzawa 2006). Thus, the role of leptin is not fully 
known, and under active review.  
 
1.4.1  Metabolic Syndrome X 
Metabolic syndrome, or syndrome X, first termed by Reavan in 1988 coins together physiological 
disorders associated with obesity, and specifically abdominal/visceral obesity. Although there is 
debate on the exact parameters, conditions such as insulin resistance and resulting dyslipidaemia 
(including hypercholesterolemia and hypertriglycerolemia), hyperglycemia, and hypotension are 
inclusive to this definition (Shaw et al. 2005, Sorrentino 2005). These abnormalities are further 
associated with physiological aberrations such as cancer, diabetes, and heart disease.  
 
The concept of the metabolic syndrome allows for a comprehensive approach towards obesity in 
terms of investigating pathogenic relationships (Shaw et al. 2005). It may also be used as a 
preliminary diagnostic to determine the risk for heart disease and diabetes, thus facilitating 
implementation of appropriate treatment plans of which diet and exercise are important components 
(Stone and Saxon 2005, Sorrentino 2005).  
 
Pathological origin of this condition is yet to be determined as the many complex relationships 
between several disorders seemingly precede one another, although insulin signaling pathways are a 
convincing common point (Shaw et al. 2005). From here, metabolic dysfunctions cascade and 
upregulate each other, creating favorable circumstances for carcinogenesis. From a single cell 
perspective, physiological disorder affects functioning of signaling pathways, ultimately disrupting 
the balance between proliferation and apoptosis.  
 
1.5   Animal Models 
Animal models provide the opportunity to study the biology of disease processes in a physiologically 
relevant state to humans. Along with the disease pathology itself, cellular and molecular events may 
be targeted in a somewhat environmentally and genetically controlled system (Green and Hudson 
2005). Moreover, animal models offer valuable preliminary data upon which human clinical trials can 
be based. Further advantage of using an in vivo model is that tumor biology with regards to three-
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dimension morphology, angiogenesis, metastasis, and tissue interaction may be studied in a relevant 
physiological setting (van Weerden and Romijn 2000). Although, animal studies should always be 
evaluated with regards to how relevant they are to human conditions, and how predictive they can be 
for the disease process (Green and Hudson 2005). 
 
With regards to colon carcinogenesis, molecular and pathological similarities to the human condition 
should be observed in order to have an effective model (Reddy 2004). Among the most widely used, 
include the carcinogen injected azoxymethane rodent model and ApcMin mice model. Zucker obese 
rats, traditionally used to study obesity and related metabolic disorders, offer a novel way of studying 
the progression of cancer in an altered physiological state. 
 
Azoxymethane Model 
Malignant transformation of cells may be induced by a variety of agents such as irradiation, 
oncogenic manipulation and chemical carcinogens, the latter of which are commonly used for animal 
studies (Corpet and Pierre 2003). These may act directly to either initiate carcinogenesis, or require in 
vivo metabolism for activation (Cotran et al. 1999). Procarcinogen 1,2-dimethylhydrazine (DMH) and 
its metabolite, azoxymethane (AOM), (Figure 1-5), are commonly used hydrazine carcinogens that 
are metabolized into methylazoxymethanol (MAM), first identified and isolated from the cycad 
flower by Laquer and Spatz (1963). In turn, MAM is converted to methyldiazonium which can induce 
neoplastic transformation via methylation of DNA, RNA and proteins of colonic epithelial cells 
(Greene et al. 1987).  
 
AOM and MAM are conveniently used colon specific carcinogens of choice that are easily prepared 
in saline solutions, and injected into rats subcutaneously at optimal dosages of 10-20mg/kg body 
weight (Bird 1998). Rats are the species of choice for these studies as they are more responsive to the 
carcinogen than mice which require several administrations to develop colonic tumors. Sprague-
Dawley and Fischer F344 rats are common strains to study AOM initiated colon cancer (Nauss et al. 
1987). 
 
Historically the AOM model has provided valuable information on colon cancer, and has been used in 
numerous studies testing different chemopreventative agents (Reddy 2004). Furthermore, AOM-
induced ACF and tumors exhibit similar histopathological characteristics to those found in humans 
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(Franks and Teich 2001). Moreover, tumors induced by AOM similar have mutations in K-ras and β-
catenin genes, but seldom in the Apc gene, and almost never at p53 (Green and Hudson 2005). A 
limitation of the AOM model is that the cancer itself is of murine origin, rather than human, and it is 
specifically induced by a chemical (Pocard et al. 1996). 
  
Studies looking at ACF as an endpoint biomarker require a duration of 8 weeks after AOM injection, 
while a 24-52 week period is sufficient to observe tumor formation. About 5-10 animals per group are 
desirable to achieve statistical significance, and adequately study characteristics of the colonic lesions 












Figure 1-5: Chemical structure of AOM. 
Colon specific carcinogen AOM is metabolized into methyldiazonium, which induces neoplastic 







Zucker-Obese Animal Model 
There is substantial epidemiological evidence supporting a strong correlation between obesity 
associated metabolic disorders with an increased risk of colon cancer (Giovannucci 2001, Gerber and 
Corpet 1999). Zucker obese (Zk-Ob) rats are an excellent model of human obesity, and provide an 
ideal opportunity to study colon carcinogenesis in an altered physiological state (Figure 1-6).  
 
The journey of the Zucker or “fatty” rat began as a spontaneous mutation in a single recessive gene 
(Fa allele is designated as normal, while fa is the fatty mutation) in the laboratory of Zucker and 
Zucker (1961). Zk-Ob rats inherit obesity as an autosomal Mendelian recessive trait, fa/fa 
homozygous for nonfunctional leptin receptors, in comparison to their lean (Fa/fa or Fa/Fa) 
counterparts (Bray 1977). Leptin, a peptide hormone produced by adipocytes, regulates body weight 
and fat metabolism by sending signals to the hypothalamus to suppress appetite (Moore and Dalley 
1999). Obesity in these rats is associated with metabolic dysfunction of fat as seen by lactescence and 
an increased amount of adipose tissue (Zucker and Zucker 1962). Genetic association of fa gene to 
obesity is confirmed as Zk-Ob rats on low fat or energy restricted diet also exhibit these symptoms. 
Interestingly, female Zucker rats are sterile, which has implications for breeding programs.  
 
Average weights of these animals at 40 weeks is 800g and 625g for Zk-Ob, and 480g and 295g for 
Zucker lean (Zk-Ln), males and females respectively (Zucker and Zucker 1962). Zk-Ob rats exhibit 
hyperphagia, hypertriglyceridemia, hypercholesterolemia, hyperinsulinaemia and mild hyperglycemia 
at about six weeks of age. Pathological findings at death often include hydronephrosis and polycystic 
kidneys, as well as fatty livers (Zucker and Zucker 1962). It has been shown that Zk-Ob rats are more 
sensitive to chemically induced colon carcinogenesis in comparison to their lean counterparts (Raju 
and Bird 2003). Since there is little difference in ACF number between Fa/fa and Fa/Fa animals, the 
recessive gene linked to leptin receptor deficiency is not solely responsible to higher susceptibility of 
colon cancer (Weber et al. 2000). Use of this animal model will help to understand carcinogenesis in 
relation to obesity and associated metabolic disorders, providing valuable information for treatment 
















Figure 1-6: Zucker obese rat and its lean counterpart. 
Zk-Ob rats inherit obesity as an autosomal Mendelian recessive trait, fa/fa homozygous for 
nonfunctional leptin receptors, as compared with their lean (Fa/fa or Fa/Fa) counterparts. Zk-Ob rats 
are an excellent model of human obesity, and provide an ideal opportunity to study colon 
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Tumor Necrosis Factor-α 
2.1 Background 
Tumor necrosis factor-α (TNF-α), a pleiotropic, pro-inflammatory cytokine part of the TNF ligand 
superfamily, is produced primarily by immune cells such as macrophages, neutrophils, natural killer 
cells, T and B lymphocytes, as well as tumor cells (Anderson et al. 2004). TNF-α plays a key role in 
the inflammatory process and modulates tissue damage and restoration via different mechanisms 
including chemokine and cytokine promotion, as well as extravasation of leukocytes (Varfolomeev et 
al. 2004, Balkwill 2002).  
 
Excessive levels of TNF-α are associated with pathological disorders related to pro-inflammatory 
conditions such as arthritis and inflammatory bowel disease (Wajant et al. 2003). Inhibition of this 
cytokine in these circumstances has been observed to be beneficial. Additionally, TNF-α plays pivotal 
roles in cell death and survival signaling mechanisms, and is a key target for understanding cancer 
progression and related treatment strategies.  
 
History 
Coley’s observation of tumor regression in patients when injected with bacterial cultures contributed 
to the concept of the immune response towards cancer (Coley 1906). Upon further study, TNF-α was 
identified and associated as one of the key molecules involved in this observation. cDNA of TNF-α 
was cloned in 1984, upon which its structural similarity to lymphotoxin was demonstrated (Pennica et 
al. 1985).  
 
Since then, much attention has been focused on the potential of TNF-α as a possible cancer 
therapeutic as exogenous treatment with this cytokine has potent anti-tumor properties (reviewed in 
Balkwill 2002). Direct injection of TNF-α is associated with necrosis and vascular damage to 
xenograft tumors in mice, effects which are amplified with the addition of interferon (IFN). Induction 
of apoptosis, mediation of CD8+ T cells, and inhibition of angiogenesis in tumors are further 
consequences of TNF-α therapy (Balkwill 2002).   
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However, the highly toxic side effects of TNF-α such as organ failure and hypotension, in addition to 
the effective dose being much higher than the tolerated dosage, limit the usage of this cytokine in 
cancer therapy (Lejeune et al. 1998). Currently, TNF-α treatment involving hemorrhagic necrosis of 
tumors is approved for soft tissue sarcomas and superficial lesions in Europe (Anderson et al. 2004). 
 
2.2 TNF-α and Cancer  
TNF-α has contradictory effects with regards to cancer therapy; tumor regression is observed with 
exogenous administration of high doses, while endogenous levels of TNF-α is associated with 
promotion of tumor growth (Anderson et al. 2004). This is perhaps one of the most interesting aspects 
of the TNF-α and cancer relationship, and has been subject to great scientific controversy. The dual 
effects of TNF-α may be correlated to its signaling pathways which mediate both cell death and 
survival, and will be discussed further on.   
 
High levels of TNF-α present in the tumor microenvironment promote conditions conducive to 
inflammation and cancer. Interestingly, TNF-α mediates changes in tumor architecture in a manner 
similar to the inflammatory response, and stimulates fibroblast production and changes to tumor 
angiogenesis (Balkwill 2002). TNF-α also induces DNA damage through inhibition of DNA repair 
enzymes and stimulation of inducible Nitric Oxide synthase (iNOS). Continuous exposure of HT-29 
colon adenocarcinoma cells to TNF-α results in increased production of ROS via iNOS, an effect that 
is known to augment tumor development (Seidelin and Nielson 2005). 
 
Tumor cells can contribute to TNF-α production and manipulate surrounding cells to secrete more 
cytokines, facilitating tissue damage (Dranoff 2004). The communication between cancer and normal 
cells further plays critical roles in initiating signaling pathways that may result in cell death or 
survival.  
 
TNF-α mRNA has been detected in a variety of cancers, and clinical observations have demonstrated 
high protein levels in the plasma of cancer patients (Balkwill 2002). In addition, individuals having an 
advanced stage of disease have higher levels of TNF-α in comparison to those at earlier phases 
(Anderson et al. 2004). Interestingly, the association between malignancies and high plasma cytokine 
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levels has been substantiated by the increased frequency of a single nucleotide polymorphism at TNF-
308 (Warzocha et al. 1998).  
 
The role of TNF-α as a pro-cancerous cytokine has also been extensively studied in mice models 
using DMBA as a DNA damaging tumor inducer, and TPA/okadaic acid as a tumor promoter 
(Suganuma et al. 1999). TNF-α deficient mice had only 10% tumor incidence and delayed onset of 
tumors in comparison to the 100% incidence in control mice. TNF-α knockout mice being more 
resistant to tumor development further reinforces the pro-cancerous consequences of this cytokine 
(Suganuma et al. 1999). 
 
Due to the role of TNF-α in cancer and inflammation related diseases, development and testing the 
efficacy of inhibitory drugs is of great interest. There are currently two TNF-α inhibitors that are 
licensed for clinical trials in the US for rheumatoid arthritis and Crohn’s disease. Infliximab (also 
known as Remicade and Centocor) is a murine monoclonal antibody with a 75% humanized 
homology, and neutralizes human TNF-α by binding to it, and preventing receptor activation 
(reviewed in Braun and Sieper 2003). Etanercept (also known as Enbrel or Immunex), another TNF-α 
inhibitor,  mimics solubilized human TNFR2 receptor - the Fc portion of human immunoglobulin is 
fused with extracellular portion of the receptor- and binds TNF-α (reviewed in Balkwill 2002). Safety 
and efficacy of this drug has been studied in phase II clinical trials for metastatic breast carcinoma, 
and the incorporation of Etanercept in chemotherapy is being considered (Madhusudhan et al. 2004).  
 
These drugs are effective in alleviating symptoms of inflammation via inhibition of cytokine 
production, leukocyte infiltration, as well as angiogenesis (Charles et al. 1999). As inflammation and 
cancer share an intimate relationship, further investigation into using TNF-α inhibitors in a 
complimentary approach towards the two diseases is warranted.  
 
2.3 TNF-α Structure  
TNF-α is produced as a homotrimeric transmembrane protein, and then released in soluble 
homotrimeric form by TNF-α converting enzyme (TACE), a membrane bound metalloproteinase 
(MMP) (Wajant et al. 2003). Protomers of TNF-α are 17kDa each and composed of two anti-parallel 
beta sheets (Ecks and Sprang 1980). Both soluble and membrane bound forms of TNF-α exist, and 
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bind primarily with tumor necrosis factor receptor-1 (TNFR1) and tumor necrosis factor receptor-2 
(TNFR2) receptors respectively (Varfolomeev and Ashkenazi 2004).  
 
2.4 TNF-α Receptors 
TNF-α mediates its effects through receptors TNFR1 (CD120a) and TNFR2 (CD120b) with 
molecular weights of 55-60 and 75-80 kDa respectively (Hohmann et al. 1989). The TNF-α receptors 
share very little homology, indicating that they may mediate different functions (Beyaert et al. 1994). 
Unlike TNFR1 which is commonly expressed in most cells, especially those of epithelial origin, 
TNFR2 is quite regulated and found mainly in immune and haematopoetic cells (Wajant et al. 2003). 
Interestingly, both receptors can bind lymphotoxin, most probably due to its structural similarity with 
TNF-α. Other cytokines such as interleukins (IL) and IFN can regulate TNFR expression as well 
(Higuchi and Aggarwal 1994a). 
  
Signals mediated through TNFR are diverse, and may also have similar effects through distinct 
mechanisms. Depending on the outcome of the signaling pathway, activation of single or both 
receptors must occur (Thommesen and Laegeid 2005). Functional differences between TNFR1 and 
TNFR2 concerning cytotoxicity, DNA damage, and macrophage differentiation have been observed 
(Higuchi and Aggarwal 1994b). In some instances, the two receptors have opposing effects; while 
TNFR2 promotes cell survival, TNFR1 is more favorable towards mediating cell death (Fontaine et 
al. 2002). Cells lines expressing either TNFR1 or TNFR2 were used to confirm that cytotoxicity is 
mainly mediated through TNFR1 (Higuchi and Aggarwal 1994b). Lack of a cytoplasmic death 
domain in TNFR2 is attributed to its preferential cell survival signaling. 
 
2.4.1 Soluble Receptors 
While TNF-α receptors are mainly membrane bound, they can also be found in active soluble form, 
mimicking paracrine type actions (Lotz et al. 1996). Extracellular domains of receptors may be 
cleaved by TACE, leaving soluble fragments which have capacity to neutralize circulating TNF-α 
(Keith et al. 2000, Wajant et al. 2003). Soluble forms of both TNFR1 (sTNFR1) and TNFR2 
(sTNFR2) have the ability to bind, as well as release TNF-α, although membrane bound TNF-α is 
more keen towards activating sTNFR2. (Teddy et al. 1994). This in turn can have two effects: 1) 
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soluble receptors act as inhibitors by binding to TNF-α, thus rendering it unavailable, or 2) they act as 
reservoirs for TNF-α, releasing it slowly and prolonging its biological effects. While response (1) is 
seen with high receptor concentrations, lower concentrations of soluble receptors stabilize the 
structure of TNF-α and actually augment its activity (Aderka et al. 1992). Unlike sTNFR2, sTNFR1 
expression seems to be more indifferent towards responding to circulating TNF-α (Vandenabeele et 
al. 1995). 
 
Usually the effects of soluble receptors are most critical in an environment of high cytokine 
production, as they can augment the biological activity of TNF-α (Rojas-Cartagena et al. 2005). 
Increased numbers of soluble receptors in colitis for example, increase and prolong TNF-α activity, 
thus enhancing the detrimental effects to the colon. Interestingly, the shedding of TNFR2 was more 
closely associated with colonic damage rather than TNFR1 in mice with colitis (Rojas-Cartagena et 
al. 2005).  
 
Desensitization of receptors towards TNF-α is also possible, and occurs through internalization of 
TNFR1 and shedding of TNFR2 (Higuchi and Aggarwal 1994a). Prolonged exposure to TNF-α in U-
937 cell line downregulated receptor expression in a time and concentration dependant manner. 
Number of receptors, but not their affinity, was decreased. Why the TNFR2 is shed as opposed to 
TNFR1 is not known. Evaluating levels of both membrane bound and soluble receptor forms is 
important when investigating the biological function of TNF-α (Higuchi and Aggarwal 1994a). 
 
Soluble receptors are regarded as potential indicators of cancer due to high amounts shed by tumors, 
and may be correlated to disease progression (Langkopf and Atzpodien 1994). Levels of soluble 
receptors are increased in patients with ovarian cancer in comparison to those with benign lesions 
(Gadducci et al. 1995). Furthermore, patients with melanomas also showed high levels of sTNFR1, 
while a predominant amount of sTNFR2 was observed especially in metastatic lesions (Viac et al. 
1996).  
 
2.5 TNF-α Signaling Pathways 
Upon binding to its receptors, TNF-α initiates signaling cascades mediating both cell death and 
survival. This dual effect of TNF-α has been under great speculation, and is particularly of interest in 
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conditions such as cancer where dysregulation of cell death contributes to disease progression. 
TNFR1 and TNFR2 can initiate both apoptotic and cell survival signaling cascades, and are discussed 
below.  
 
TNFR1 Signaling Pathway 
A model of the TNF-α signaling pathway mediated through TNFR1 is extensively described by 
Ashkenazi and Dixit (1998) and describes the formation of two intracellular complexes upon ligand- 
receptor binding (Figure 2-1). A cell survival signal is elucidated via stimulation of NF-κB by the 
first complex, while the second induces apoptosis through caspase activation. If this second complex 
is removed from the initial receptor complex, its effects may be counteracted via signaling of other 
anti-apoptotic gene products from the NF-κB pathway (Micheau and Tschopp 2003).  
 
Formation of complex 1, which is plasma membrane bound, involves the death domains (DD) of 
TNFR1 to recruit TNF Receptor 1 associated death domain (TRADD) adapter molecules. TRADD 
then activates receptor interacting protein (RIP), which can activate the MAPK/JNK pathway via 
TNF Receptor Associated factor 2 (TRAF2) activation. The NF-κB pathway may also be initiated at 
this point, and induce a cell survival signal (Ashkenazi and Dixit 1998, Micheau and Tschopp 2003).   
 
Complex 2, a cytoplasmic complex, originates when complex 1 starts to dissociate. As the TRADD 
and RIP detach, their DD are fee to bind with other molecules such as Fas associated death domain 
(FADD). Joining of FADD with TRADD enables caspase 8 recruitment, resulting in apoptosis 
(Micheau and Tschopp 2003). Importantly, complex 2 formation is dependant on FADD, which can 
also be recruited to the membrane by Fas ligand (FasL) (Ashkenazi and Dixit 1998). Apoptosis may 
be also initiated via caspase 2 through the binding of RIP associated Ich-1/CED with death domain 
(RAIDD) to the RIP and TRADD complex, further emphasizing that different components of DD and 
adaptor molecules may mediate the signal to be elicited (Duan and Dixit, 1997).  
 
Thus, the outcome of the TNF-α signaling pathway is dependant on the modification of the initial 
TNF-α/TNFR1 complex 1; dissociation of this complex results in apoptosis, while the intact complex 
mediates cell survival though the NF-κB pathway. While factors affecting this decision are still being 
speculated, a possible influence is the FasL which facilitates the migration of FADD to the plasma 
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membrane. Downregulation of the FasL has also been associated with enhanced cancerous growth in 
vivo (Philips et al. 2004). 
 
The FLICE inhibitory protein (FLIPL) switch, a potent inhibitor of TNF-α mediated apoptosis via 
blocking caspase 8, is another candidate that may affect the outcome of the signaling pathway 
(Micheau and Tschopp 2003). Complex I stimulates increased expression of FLIPL along with 
inhibitor of apoptosis proteins (IAP) via NF-κB transcriptional activity. If NF-κB pathway is not 
initiated however, the FLIPL activity diminishes and is not able to prevent caspase activation and 
resultant cell death. FLIPL production and availability is dependant on the activation of NF-κB, 
thereby creating a checkpoint in the signaling pathway (Micheau and Tschopp 2003). In addition, 
cells that cannot produce FLIPL may eventually be eliminated via TNF-α mediated apoptosis. It 































































Figure 2-1: TNF-α signaling pathway via TNFR1. 
Schematic representation of pathways initiated by the TNF-α and TNFR1 complex: Complex 1 
initiates a cell survival pathway via NF-κB and MAPK/JNK activation. Dissociation of Complex 1 
leads to formation of Complex 2, which is conjugated with FasL recruited FADD. As a result, caspase 
8 and 10 are recruited to induce apoptosis. FLIPL, transcribed by NF-κB, is a potent inhibitor of 







TNFR2 Signaling Pathway 
TNFR2 receptor lacks death domain complexes, thus activation of NF-κB is usually associated with 
TRAF1, 2, 3, and upregulation of cIAP. Conversely, TNFR1 interacts with death domains of 
TRADD, FADD and RIP adapter molecules. Signals elicited by the two receptors with regards to NF-
κB activation are distinct, and inhibitors of TNFR1 mediated NF-κB activation have no effect on 
TNFR2 signaling (Thommesen and Laegeid 2005). TNFR2 may also mediate TRAF2 degradation, 
favoring the apoptotic outcome (Varfolomeev and Ashkenazi 2004). This may be confirmed with the 
earlier stated observation that occurrence of TNF-α associated DNA fragmentation requires a signal 
from TNFR2 (Higuchi and Aggarwal 1994b). Although the mechanisms of the pathway elicited 
through TNFR2 are still being clarified, it has been observed that activation of both receptors 
increases the apoptotic effect of TNF-α (Wajant 2003). 
 
Thus, the TNF-α stimulus and resultant complex formation may interact and affect the final outcome 
of cell death or survival, demonstrating the importance of signaling and communication within the 
cell. Once stimulated, TNF-α can initiate a negative feedback signal to terminate the pathway via 
downregulation or solubilization of receptors (Balkwill 2002). Continuous binding of TNF-α to its 
receptors in aberrant physiological circumstances can promote inflammation and cancer.  
 
Sphingo-ceramide Pathway 
The sphingo-ceramide pathway initiates upon TNF ligand-receptor binding and involves activation of 
phosphatidylcholine-specific phospholipase C, leading to the production of 1,2-diacylglyercol 
(DAG). In turn, DAG stimulates the production of ceramide via acidic sphingomyelinases present in 
cell endosomes (Schutze 1995). Ceramide may then induce NF-κB activation via IκB degradation 
(Yang et al. 1993).   
 
2.6 TNF-α and Obesity 
Obesity, associated with a number of diseases such as cancer and heart disease, is also accompanied 
by physiological dysfunctions such as abnormal metabolism and elevated productions of hormones 




Chronic elevation of TNF-α, TNFR1, and TNFR2 in an obese physiological state have been observed 
in both obese human and animal studies (Samad et al. 1999, Hotamisligil et al. 1993). High plasma 
concentrations of TNF-α determined by ELISA, and mRNA expression in adipocytes via Northern 
blot (Hotamisligil et al. 1993), and RT-PCR (Hoffman et al. 1994) are documented. Furthermore, 
these studies have established that elevated levels of TNF-α in an obese state contribute to insulin 
resistance (Samad et al. 1999). Interestingly, an increased responsiveness to insulin was seen upon 
neutralization of TNF-α, and animals injected with a recombinant, soluble TNFR presented a two to 
three fold increase in insulin mediated glucose metabolism (Hotamisligil et al. 1993). Additionally, 
treatment of animals with an insulin sensitizer decreased TNF-α and TNFR mRNA expression, 
suggesting a working relationship between TNF-α and insulin resistance (Hoffman et al. 1994).  
 
Effects of TNF-α on lipid metabolism have also been studied, yet results are conflicting. Although a 
high TNF-α level may be associated with cachexia, it is also known to stimulate lipogenesis, and 
modulate lipid and glucose metabolism (reviewed in Hotamisligil et al. 1993). Conversely, TNF-α 
can also mediate apoptosis in adipocytes of obese mice (Nelson-Dooley et al. 2005).  
 
2.7 TNF-α and HT-29 Colon Cancer Cells  
One of the first colon adenocarcinoma cells lines, HT-29, was developed in 1964 by Jorgen Fogh 
from the Memorial Sloan-Kettering Cancer Center, New York (Fogh and Trempe 1975). This cell 
line offers a valuable model system to study colon carcinogenesis, and is used extensively to screen 
and evaluate the efficacy of chemopreventative agents. Response of HT-29 cells to TNF-α is similar 
to those of freshly isolated intestinal epithelial cells, making them relevant for studying actions of this 
cytokine (Jung et al. 1995).  
 
HT-29 cells are relatively resistant to TNF-α mediated cytotoxicity unless exposed to extremely high 
concentrations, or prolonged exposure times in comparison to other colon cancer cell lines (Vaculova 
et al. 2002). When exposed to 10ng/mL TNF-α during a 3 week time period to look at chronic effects, 
no obvious morphological changes, and marginal decline in cell growth was observed (Bruno and 
Kaetzel 2005). In general, effects of TNF-α on other cancer cells are usually seen either very quickly 




Apoptosis due to extensive TNF-α treatment in a reduced serum environment is accompanied by poly 
(ADP ribose) polymerase (PARP) cleavage (Vaculova et al. 2002). PARP, a 113 kDa DNA repair 
enzyme cleaves into 85 and 25 kDa fragments during apoptosis.   
 
Cancer cell lines become more responsive to TNF-α mediated cytotoxicity with the addition of other 
agents like IFN-γ and α (Kimura et al. 2003). IFN-γ also augments TNF-α impairment of the 
epithelial barrier functionality in HT-29 cells (Schimtz et al. 1999). Additionally, TNF-α and IFN-α 
have been shown to enhance expression of the FasL, which may contribute to their strong cytotoxic 
effect. Interestingly, this combination also activates NF-κB more strongly than the individual 




Nuclear Transcription Factor-κB 
3.1 Background 
Upon environmental stimuli, cells recognize and activate intrinsic pathways, creating a response 
appropriate for maintaining a homeostatic balance. In order for this biological consequence to 
succeed, transcription factors controlling gene expression play a significant role in regulating 
communication between the stimulus and final outcome.   
 
Nuclear transcription factor-κB (NF-κB) is a transcription factor having multiple roles in different 
biological processes (Figure 3-1). Genes transcribed by NF-κB have numerous functions and 
dysregulation results in physiological impairments such as inflammation and cancer (Lin and Karin 
2003). In addition, crucial roles of NF-κB in the regulation of cell death and survival have been linked 
to carcinogenesis, thus making the many components of the NF-κB signaling pathway targets for 
cancer therapies.  
 
Ubiquitous cytoplasmic expression of dormant NF-κB is found in all cell types. Upon activation of 
the signaling pathway, NF-κB translocates to the nucleus and binds to the promoter region of target 
genes to induce transcription (Viatour et al. 2005). Gene products that are generated by NF-κB 
activation are diverse, and further influence cell death and survival (Lin and Karin 2003). As 




















Figure 3-1: Multiple Roles of NF-κB. 
Under normal circumstances, NF-κB regulates immune activity and cell division. Conversely, 
dysregulation is associated with inflammation and cancer promotion via cell proliferation, 










NF-κB and DNA binding was first observed in 1986 in murine B cells (Sen and Baltimore 1986). 
Soon after, the inhibitor of NF-κB (IκB) subunit was identified as a inhibitory molecule which 
localizes NF-κB in the cytoplasm, and could be dissociated by treatment with certain detergents 
(Baeuerle and Baltimore 1988). Gene cloning of different NF-κB subunits such as p50/p105 took 
place in the1990s in different laboratories, and paved the way for identifying other parts of NF-κB 
family (reviewed in Seibenlist et al. 1994). 
 
3.2 Components of NF-κB Pathway 
 
NF-κB Subunits 
NF-κB exists as dimers consisting of the following subunits: RelA (p65), RelB, c-Rel, NF-κB1 
(p105/p50), and NF-kB2 (p100/p52). All subunits have Rel homology domains (RHD), a common, 
conserved sequence of 200 amino acids involved in binding the subunits together, as well as with 
DNA, and the inhibitory IκB molecule (Viatour et al. 2005). Only the RelB subunit does not form 
homodimers, while the p105 and p100 are processed into p50 and p52 DNA binding subunits post 
translation. The mechanism of p105 and p100 processing is unclear, although the N terminus 
containing the RHD binds to DNA while the C terminus is degraded (Siebenlist et al. 1994). 
  
Properties of the NF-κB dimers vary depending on their composition, and can either activate or 
suppress gene transcription, or both (Bonnizi and Karin 2005, Perkins and Gilmore 2006). For 
example, homodimers of p50 or p52 subunits are weak gene activators in comparison to their 
heterodimerized form with p65 (Siebenlist et al. 1994). Additionally, characteristics such as 
expression, rate of nuclear translocation and location of κB binding sites are influenced by dimer 
composition (Molitor et al. 1990).     
 
IκB 
NF-κB dimers are bound at the RHD to IκB inhibitor molecules which prevent nuclear translocation. 
IκB also works by inhibiting the extrinsic nuclear localizing signal of NF-κB, thus further preventing 
its migration to the nucleus (Foo and Nolan 1999). 
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IκB exists in different forms (IκBα, β, γ, ε, and ζ, and BCL3), all of which have ankyrin repeats that 
facilitate binding to the RHD (Nakanishi and Toi 2005). Interestingly, the p105 and p100 NF-κB 
subunits also have these same ankyrin repeats, and can function as inhibitors of NF-κB as well 
(Bonizzi and Karin 2005). Different forms of IκB may preferentially interact with specific dimers; 
IκBα and β combine with p65/p50 and Rel/p50 subunits, while BCL3 joins with p50 and p52 (Foo 
and Nolan 1999). 
 
Upon activation of the signaling pathway, IκB is phosphorylated and the NF-κB subunits migrate to 
the nucleus where they can transcribe genes for IκB. As a result, cytoplasmic levels of IκB are 
replenished. This negative feedback contributes to inhibiting further NF-κB activation (Foo and 
Nolan 1999). The newly transcribed IκB can also bind to nuclear NF-κB and re-shuttle it back to 
cytoplasm, thus terminating transcriptional activity (Hayden and Gosh, 2006). IκBβ and ε are not 
transcribed by NF-κB, and can also contribute indirect to negative feedback (Hoffman et al. 2002).  
 
The role of IκB is not essential in all cell types. In B lymphocytes for example, levels of NF-κB in the 
nucleus are constitutive, thus making IκB degradation non-essential for NF-κB activation (Doerre and 
Corley 1999).  
 
IKK 
IκB kinase (IKK) is important for the phosphorylation of IκB-NF-κB complex, thereby freeing NF-
κB and facilitating its move to the nucleus. Previous studies have demonstrated that out of the three 
kinds of kinases, α, β, and γ, IKKβ is more functional in the cytokine induced pathway, IKKα in the 
alternative pathway, while IKKγ (also referred to as NF-κB essential modulator, NEMO) regulates 
the other two kinases (Russo et al. 2002, Hayden and Ghosh 2006). Dominant negative expression of 
IKK has been demonstrated to block the NF-κB signaling cascade (Russo et al. 2002). Interestingly, 
IKK can also affect other transcription factors and pathways involving histones, and estrogen 
receptors (reviewed in Perkins and Gilmore 2006). 
3.3 NF-κB Signaling Pathways  
There are two NF-κB pathways, Classical/Canonical and Alternative, which are thought to be 
distinctly involved in innate or adaptive immunity respectively. The classical pathway is stimulated 
by cytokines such as TNF-α, while the alternative pathway involves activation by members of TNF-α 
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superfamily (excluding TNF-α) and receptors such as lymphotoxin-β and C-cell activating factor 
(Bonnizzi and Karin 2004). The sequential steps of these pathways are observed to be cell specific, 
and continue to be explored and verified. 
 
Different components of the NF-κB pathway are observed to be essential for the outcome of cell 
death or survival. For example, presence of the NF-κB p65 subunit is necessary for cells to resist 
toxicity from TNF-α (Beg and Baltimore 1996). 
 
Classical Pathway 
The classical/canonical pathway of NF-κB is associated with innate immunity, and results in 
transcription of molecules such as chemokines, cytokines, and cell adhesion molecules (Viatour et al. 
2005). Along with pro-inflammatory cytokines such as TNF-α, pathogens may also initiate this 
pathway, and stimulate the production of mediator molecules directing phagocytosis (Bonnizi and 
Karin 2005).  
 
Upon the binding of TNF-α and TNFR1, the silencer of death domain (SODD) is released and 
transfers adapters TRADD, RIP and TRAF2 onsite. This in turn stimulates the recruitment and 
modification of the IKK complex consisting of IKKα and β conjugated with NEMO/IKKγ (Perkins 
and Gilmore 2006). Phosphorylation of IKKγ and IKKβ initiates phosphorylation of IκB at Ser 
residues 32 and 36. Ubiquitinized proteosome degradation of IκB enables the dissociation of the NF-
κB/IκB complex, allowing the free NF-κB dimer to migrate into the nucleus and stimulate gene 
transcription (Figure 3-2) (Viatour et al. 2005). NF-κB may upregulate its own expression, which is 
often seen in pathological dysfunctions such as inflammation and cancer. Conversely, negative 







































Figure 3-2: Simplified representation of the classical NF-κB Pathway. 
Upon a stimulus from TNF-α, the IKK complex is recruited and phosphorylated, leading to 
phosphorylation and proteosome degradation of IκB. NF-κB dimers are then free to migrate into the 
nucleus and initiate transcription of genes important for cell death or survival. Negative feedback 






The alternative or CD40 pathway is associated with adaptive immunity as well as development and 
maintenance of lymphoid organs. This pathway is triggered by lymphotoxin β and TNF homologues, 
and involves the phosphorylative activity of IKKα (Lin and Karin 2003). 
 
Binding of the CD40 ligand to its receptor results in the recruitment of TRAF, and activation of NF-
κB-inducing kinase (NIK), a serine/threonine kinase which stimulates IKKα. The inhibitory subunit 
p100 is then processed at the c terminus into the p52 subunit. Subsequently, the N terminal consisting 
of the RHD becomes available to bind with RelB to form a dimer and translocate to the nucleus 
(Bonnizi and Karin 2004). This pathway is NEMO independent, and requires the presence of IKK 
homodimers (Viatour et al. 2005). 
 
A third pathway, referred to as the Atypical pathway, has also been described, and is triggered by 
DNA damage. This pathway is IKK independent, and relies on proteosomes to degrade IκB directly 
(Viatour et al. 2005).  
 
3.4 NF-κB and Pro-Apoptosis 
NF-κB signaling pathways are generally associated with cell survival. Anti-apoptotic genes that are 
induced include IAP, cFLIP, A1, Bcl-2, TRAF1 and 2, while pro-apoptotic Bax gene may be 
inhibited (Lin and Karin 2003). Continual activation of these in tumor cells further promotes 
tumorigenesis, metastasis, angiogenesis (as reviewed in Perkins and Gilmore). Upon entering the 
nucleus however, NF-κB can also induce transcription of several pro-apoptotic genes such as p53 
tumor suppressor gene, Fas, and caspases (Ryan et al. 2000). 
  
This dual effect of NF-κB is a result of many factors including the stimulus that initiates the pathway 
(Perkins and Gilmore 2006). Additionally, the same gene may be stimulated or inhibited depending 
on the activity and phosphorylation of the subunits (Viatour et al. 2005). Once cleaved, p65 can 
modulate gene expression by recruiting histone acetylases which promote gene activation, or 
deacytlases, which inhibit gene expression. Phosphorylation of NF-κB subunits is critical for the 




Dimer composition itself plays a significant role in influencing gene transcription (Perkins and 
Gilmore 2006). While p65 NF-κB increases expression of cIAP proteins and decreases caspase and 
death receptor expression, the c-Rel subunit has opposing effects (Chen et al. 2003). Therefore, p65 
acts as a survival subunit, while c-Rel is favorable towards apoptosis. Modulating the activity of NF-
κB subunits is a useful strategy to understand physiological implications of this pathway. 
 
Therefore, the results of NF-κB signaling pathways, whether cell survival or apoptosis, are dependant 
on many factors such as subunit properties and type of external stimuli. Regardless of outcome, if the 
activity of NF-κB is dysregulated, physiological aberrations result. Continuous activation of NF-κB 
for example, is well associated with chronic inflammation and cancer.  
  
3.5 TNF-α and NF-κB Crosstalk 
The TNF-α and NF-κB pathways have much overlap in cell survival and apoptosis signaling. The 
apoptotic signal initiated by TNF-α is blocked by the cell survival signal by NF-κB. Inhibition of NF-
κB in order to facilitate TNF-α mediated cytotoxicity is therefore of considerable interest. 
Conversely, TNF-α itself may also stimulate the NF-κB pathway through various mechanisms, 
including dissociation of the IκB complex. Variant cells lines as well as animal models that are IκB 
deficient have been developed to study the effects and interaction of TNF-α and NF-κB (Van 
Antwerp et al. 1996). The following section will aim to summarize evidence using models of NF-κB 
inhibition in attempts to promote apoptosis in cancer cells. 
 
The p65 subunit is of significant interest as p65 -/- mice have extensive liver apoptosis resulting in 
death at 15 days (Beg and Baltimore 1996). Cells isolated from these mice do not survive upon TNF-
α treatment, while re-transfection of p65 subunit facilitates resistance to death. These results were not 
seen with the p50-/- cells. Thus, p65 is more essential than the p50 subunit in protecting cells from 
apoptosis mediated by TNF-α (Beg and Baltimore 1996).  
 
A variant line of human fibrosarcoma cells otherwise resistant to TNF-α was designed in which NF-
κB was repressed by expression of a super form of IκBα (Wang et al. 1996). Essentially, this variant 
prevented phosphorylation of IκB, thus inhibiting NF-κB from going into nucleus and binding to 
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DNA. Apoptotic cell death was observed upon TNF-α exposure to these cells, suggesting that NF-κB, 
when activated, had a protective effect (Wang et al. 1996).  
 
Sensitivity of TNF-α mediated apoptosis is variable according to cell line; while HCT-116 is quite 
responsive to cytotoxicity, HT-29, WiDR, DLD-1 colon cancer cell lines are not as sensitive (Han et 
al. 2000, Zwacka et al.2000). When looking at apoptosis during treatment with TNF-α in these cell 
lines, TNFR1 and accessory molecules such as FADD, TRADD, FLICE expression remained 
relatively constant, indicating that they were not critical factors involved in the apoptotic pathway 
(Han et al. 2000). Treatment with TNF-α resulted in a decrease in NF-κB-DNA binding that was time 
dependant. Additionally, overexpression of IκB-α resulted in growth inhibition of cells treated with 
TNF-α, providing further evidence for the involvement of NF-κB in cell survival (Han et al. 2000). 
However, the effects are variable depending on the cell lines. Why certain cell lines more responsive 
than others, and how we can use this information to further understand the interaction between 
pathways leading to cell death or survival is of interest.  
 
3.6 NF-κB and TNF-α Expression in Colon Cancer 
Activation of TNF-α and NF-κB is associated with the pathobiology and clinical outcome of colon 
cancer, and observing the expression of key players in the pathways is an ideal way to elucidate 
mechanisms of action. Immunohistochemistry (IHC) is a valuable tool for identifying spatial 
expression of molecules of interest. Higher levels of NF-κB are reported in adenomatous polyps 
versus normal tissue from human colonic biopsies via IHC analyses (Hardwick et al. 2001). In 
addition, amplified NF-κB activation in colon carcinomas versus normal mucosa has been observed 
with electrophoretic mobility shift assay (EMSA) (Kojima et al. 2004). Advanced stage carcinomas 
are seen to have higher NF-κB expression than early stages. It has been hypothesized that high levels 
of LPS and inflammatory cytokines in the rich bacterial and pathogenic environment of the colon 
further facilitate NF-κB activation (Kojima et al. 2004). 
 
Microenvironment of the tumor provides important clues as to the mechanism of disease as well as 
understanding tumor biology. Barth et al (1996) studied tumor infiltrating lymphocyte (TIL) 
expression of TNF-α, IFN, and IL in the tumor microenvironment of human colon carcinomas 
through IHC. Higher cytokine expression was seen in metastatic carcinomas versus primary tumors. It 
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may be that levels of cytokines within the tumor environment change as lesions develop and become 
metastatic, thus warranting investigation into studying successive stages of cancer for transient 
expression patterns.  
 
In addition to protein levels, separate studies have shown rats injected with MAM and 1-
hydroxyanthraquinone (HAQ) colon carcinogens to have significantly higher levels of TNF-α and IL-
α mRNA in tumors (Yoshimi et al. 1994, Baier et al. 2005). These observations further support the 
critical role of these molecules in colon cancer.  
 
Elevated expression of NF-κB and TNF-α are also linearly correlated with inflammation associated 
colon cancer (Li et al. 2005). When compared to control animals, a significant increase of active NF-
κB levels were observed in tumor bearing rats. Tumor incidence in a separate mouse model of colitis 
associated colon cancer was decreased upon deleting the IKKβ, providing further evidence for linking 
the NF-κB pathway with inflammation and cancer (Greten et al. 2004).   
 
3.7 Targeting NF-κB Pathway in Cancer Therapy  
TNF-α has potential to be an effective treatment for cancer, however, it has been observed that that 
some tumors and cancer cell lines are resistant to its effects. Increasing the dosage for cytokine 
treatment translates to clinical toxicity. However, by manipulating the gene interactions involved in 
the signaling cascades, desirable effects may be achieved (Zwacka et al. 2000). Genetic manipulation 
has potential to sensitize cells to apoptosis, and may be combined with lower doses of exogenous 
TNF-α to maximize treatment. While this has yet to show relevance for clinical settings, models have 
been created to better understand the mechanisms involved.  
 
A popular option has been to utilize super repressor forms of IκBα, which essentially inhibit NF-κB 
translocation to the nucleus. Cell death results as apoptotic genes override the inhibitory signal from 
survival genes activated by NF-κB (Zwacka et al. 2000).  
 
Additionally, the different types of NF-κB dimers formed in colonocytes also affect cell death or 
survival outcomes. Immature colon cells at the bottom of crypts express higher levels of p65/p50 and 
p50/p50 subunits, whereas surface cells primarily express p50-p50 (Tong et al. 2004). The p50-p50 
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dimer is of special importance due to its ability of inhibiting gene expression. Interestingly, high 
levels of other subunits such as p65-p50 can compete with p50-p50 for binding sites on DNA (Tong 
et al. 2004). Thus, targeting specific NF-κB dimers is a potential strategy to regulate its effects.  
 
NF-κB Pathway Inhibition 
The promotion of cell proliferation and inhibition of apoptosis are characteristics that make NF-κB a 
key player in oncogenesis, and also an attractive target for therapeutics. Among others, different 
components that have been targeted include IκB, IKK, RIP and TRAF and it is attempted to sensitize 
cells to TNF-α mediated apoptosis through these targets. There is also evidence to suggest that 
inhibition of NF-κB via these molecules may be more effective in earlier rather than late stages of 
cancer (Lin and Karin 2003). 
 
Due the involvement of NF-κB with the immune system, a concern with inhibitory drugs is excessive 
suppression of the immune system. Thus, attempts are made to design drugs to target specific 
components like IKKα that do not interfere with immune activity. As ROS also induce NF-κB via 
degradation of IκB, inhibitors of ROS can potentiate cell death, and are another possible drug target 
(Schreck 1991). The essential aim is to focus on NF-κB activity relating to cancer growth, but not 
other functions that are otherwise beneficial (Lin and Karin 2003).  
 
Considering the duality of its responses, NF-κB inhibition may also promote tumor growth (Kim et 
al. 2006, Perkins and Gilmore 2006). Thus, interaction between cancer therapies and NF-κB, 
especially in downstream signaling must be carefully evaluated. Moreover, NF-κB inhibition is 
shown to have altered outcomes depending on whether the cancer is a result of a chronic condition 
such as inflammation, or acute carcinogen exposure (Pikarsky and Ben-Neriah 2006). In an acute 
phase, NF-κB is only activated for a short duration, and is involved in promotion of apoptosis. Thus, 
inhibition under these circumstances may not be ideal. Conversely, inhibition is beneficial when 




3.7.1 NF-κB and Drug Therapy 
Drugs often stimulate many different signals that can elicit a survival or death response in the cell. By 
manipulating the mechanism action of drugs, the response may be modified towards apoptosis, a 
desirable outcome for cancer treatment (Nakanishi and Toi 2005).  
 
Conventional cancer therapeutics may promote NF-κB activation directly, as well as through 
secondary mediators such as ROS, IL and TNF-α. While this effect may be insignificant in 
comparison to the other mechanistic actions of the drug, overexpression and constant stimulation of 
NF-κB in tumors and many cancer cell lines have exhibited resistance towards cancer drugs 
(Nakanishi and Toi 2005). In other words, NF-κB can inhibit apoptosis attempted by cancer drugs, 
leading to resistance and further challenges for current treatment strategies (Bremner and Heinrich 
2002).  
 
Drugs which are inhibitors of NF-κB, and found as natural or synthetic compounds have shown some 
promise by facilitating cell death induced by another factor such as TNF-α. Concerns with these types 
of drugs include their suppressing effect on the immune system due to NF-κB inhibition. Thus, the 
goal is to design drugs that target cancer therapy, but do not interfere with immune or other functions 
of NF-κB that are otherwise beneficial (Li and Karin 2003). 
 
Using specific inhibitors of NF-κB in combination with conventional cancer drugs have increased 
efficacy, especially for colon cancer (reviewed in Nakanishi and Toi 2005). Blocking of proteosomes, 
which rapidly degrade proteins through ubiquitous-proteosome pathway, is one strategy that has 
shown promise with regards overcoming resistance encountered with cancer therapeutics. These 
prevent the degradation of IκB and subsequent translocation of NF-κB to the nucleus (Nakanishi and 
Toi 2005). For example, Cusack et al. (2001) have shown increased apoptosis in colon cancer cell 
lines by treatments of lovostatin and proteosome inhibitor PS-341. These synergistic effects were also 
observed in vivo where a 94% decrease in tumor size was seen along with an increased number of 
apoptosic cells (Cusack et al. 2001). The combination of butyrate and TNF-α also inhibits IκB 
degradation via proteosome inhibition, and is though to be mediated through inhibition of histone 





3.7.2 NF-κB and St. John’s Wort 
Natural products are under key investigation for their potential as cancer therapeutics. A wide variety 
of compound from natural sources have been identified as NF-κB inhibitors and include flavonoids, 
isoprenoids, and phenolics (Bremner and Heinrich 2002, Nakanishi and Toi 2005). Commonly seen 
mechanistic actions for these drug types include inhibition of IKK activity, nuclear translocation of 
NF-κB, and DNA binding of NF-κB (Bremner and Heinrich 2002).  
 
St. John’s Wort (Hypericum perforatum L.) is a top selling herbal medicine in North America, used 
primarily for its therapeutic role in depression. Recent investigations have established potential of St. 
John’s Wort (SJW) as a novel cancer therapeutic. The two main constituents of SJW are hypericin 
and hyperforin, which are naphthodianthrone and phloroglucinol derivatives respectively, are 
attributed to medicinal properties of SJW (Figure 3-3). Both hypericin and hyperforin are lipophilic, 
bioavailable compounds, and hypericin has a tendency to concentrate in the Golgi complex and 
endoplasmic reticulum (Agostinis et al. 2002). 
 
Hypericin has been shown to play a role in the NF-κB pathway, and may be a used as a potential 
agent to block the cell survival signal induced by this transcription factor. Specifically, hypericin 
inhibits proteosome 26S and 20S function in glioma and mammary carcinoma cells, thus preventing 
the degradation of the inhibitory IκB subunit (Pajonk et al. 2005). This was correlated to NF-κB 
inhibition in a dose dependant manner, accompanied by an increase in phosphorylated forms of IκBα. 
Consequently, hypericin prevented NF-κB binding of DNA, thus enabling pro-apoptotic stimuli such 
as TNF-α to initiate cell death signaling. Addition of caspase inhibitor z-VAD-fmk was seen to 
counteract hypericin activity (Pajonk et al. 2005). 
 
In a separate study, inhibition of NF-κB was observed in HeLa and TC10 mouse endothelial cells pre-
incubated with hypericin, and then stimulated by phorbol ester phorbol 12-myristate 13-acetate 
(PMA) and TNF-α respectively (Bork et al. 1999). TNF-α, H2O2, and PMA are stimulants of NF-κB, 
leading to initiation of signaling cascades, and eventual gene expression via NF-κB translocation to 
the nucleus (Bork et al. 1999). Effective inhibition of NF-κB when cells were stimulated by TNF-α 
was seen with 3.96μM of hypericin. This concentration is much lower in comparison to other tested 
compounds such as curcumin or parthenolide (Bork et al. 1999). Interestingly, no effect was seen 
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when cells were stimulated by H2O2, thus indicating hypericin was not acting as an antioxidant. 
Inhibition of IL-6 expression was also seen upon exposure to hypericin and TNF-α, and thought to be 
attributed to the lack of signal for IL-6 gene transcription by NF-κB (Bork et al. 1999). 
 
The effect of hyperforin on NF-κB inhibition is not yet known. Whether hypericin and hyperforin 
influence NF-κB activation in HT-29 cells, and their combined effects with TNF-α were investigated 






                    
 




Figure 3-3: Chemical structures of hypericin and hyperforin. 
Hypericin and hyperforin are naphthodianthrone and phloroglucinol derivatives respectively. 






Materials and Methods 
Unless otherwise stated, all chemicals and reagents were purchased from Sigma Chemical Co. 
(Mississauga, ON). Primary and secondary antibodies were obtained from Santa Cruz Biotechnology 
(Santa Cruz, CA, USA). 
 
4.1 Study 1: Effects of TNF-α and NF-κB inhibitors on HT-29 colon cancer cells 
4.1.1 Cell Culture 
HT-29 colon adenocarcinoma cells were obtained from American Type Culture Collection 
(Manassas, VA), and grown in McCoys 5A medium supplemented with 10% fetal bovine serum and 
1% penicillin/streptomycin (HyClone, Logan, UT). Cells were maintained in a humidified 
atmosphere of 5% CO2, at a temperature of 37ºC. All studies were done at a cell confluency of 80% 
using cell passages 4-14.  
 
4.1.2 Cytotoxicity and Cell Growth Assay 
Compounds of interest were assessed for cytotoxic potential using the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay. This assay evaluated cell viability by measuring the 
ability of the mitochondrial dehydrogenase enzyme from viable cells to cleave tetrazolium rings of 
the MTT, forming purple formazen crystals (Mueller et al. 2004). Absorbance was measured upon 
dissolving these crystals with solubilizing agent DMSO, and correlated to the percentage of surviving 
cells in comparison to the control.  
 
Hypericin (HY) and hyperforin (HP) standards were obtained from Chromadex (Santa Ana, CA). 
Methanol in these solutions were evaporated under a stream of liquid nitrogen, and reconstituted in 
ethanol. Hypericin rich (HYex) and hyperforin rich (HPex) whole plant extracts were kindly provided 
by collaborators at the University of Guelph (Guelph, ON). Recombinant human TNF-α was 




HT-29 cells were seeded in 96 well plates at a concentration of 5x104 cells/well. Following cell 
adhesion, old media was removed, and replaced with serum-free media. Cells were then exposed to 
different concentration ranges of treatments (TNF-α: 10, 20, 40, 50, 60, 80, 100ng/mL, HPex and 
HYex: 1.25, 2.5, 5, 10, 15, 20, 25 μL/mL, HY and HP: 0, 2.5, 5, 7.5, 10, 12.5, 15 μM), and control 
lanes were exposed to corresponding concentrations of 80% ethanol. Combination treatments of SJW 
and TNF-α used the following concentrations: 10ng/mL TNF-α, 2.5 μL/mL HPex, HYex, and 2μM 
HP and HY. Upon treatment periods of 24 and 48h, 20μL of MTT (5 mg/mL stock in PBS) was 
added in each well, and plates were further incubated for 5h. Subsequently, media was gently 
removed, and 200μL of DMSO was added to each well to dissolve purple formazen crystals. Plates 
were stirred on a shaker for 5min, and absorbance was recorded at 570nm using Asys UVM 340 
spectrophotometer (Montreal Biotech, Montreal, QB). As extracts were colored compounds, parallel 
blank tests were run with only media and extracts to exclude possible interferences in absorbance 
readings. The % survival was calculated as follows: % Survival: (A570 of test sample*100)/(A570 of 
control sample). All tests were performed in triplicates, repeated thrice, and expressed as means ± SE. 
 
4.1.3 Morphological Assessment  
Cells were plated in 6-well Petri dishes at 1x106 cells/well. Upon 80% confluency, media was 
replaced with serum-free medium containing either 2.5 μL/mL HPex, HYex, or 2μM HP and HY, or 
each treatment in combination with 10ng/mL TNF-α for 24h. Following a wash with PBS, cells were 
incubated for 1 min with 10μL of combined stain of 1 part each of 100μg/mL ethidium bromide 
(EtBr) and 100ug/mL acridine orange (AO) in PBS. Stains were discarded, and coverslips were 
placed in each well. Cells were viewed under the blue light filter using the Zeiss Axioport epi-
flouresence microscope (Quorom Technologies Inc., Guelph, Canada) connected to digital imaging 
system software Openlab.  
 
4.1.4 Sample Preparation  
 
Whole cell lysates 
HT-29 cells seeded in 20mm petri plates (BD Falcon, Mississauga, ON) at a concentration of 1x106 
cells/mL were grown to confluence, washed in PBS, and treated with compounds in fresh serum-free 
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media. After a 24h treatment period, media were removed and cells were washed with PBS, and 
scraped with sterile cell scrapers (BD Falcon). Cell were then pelleted at 2000rpm for 10min and 
resuspended in 500μL ice-cold RIPA buffer (50mM Tris HCl, 1%NP-40, 0.25% Sodium 
deoxycholate, 150mM Nacl, 1mM EDTA, 1mM NaF) and freshly added protease inhibitors (1ug/mL 
of Aprotinin, Leupeptin, Trypsin Inhibitor, Pepstatin, Sodium Orthovanadate) for 15minutes with 
vigorous shaking. Following centrifugation for 15min at 15K rpm, supernatant was aliquoted in pre-
chilled tubes and stored at -80ºC for further analysis.  
 
Nuclear rich fractions  
Cells were seeded, treated, scraped and washed with PBS as above. Pellets were then resuspended in 
500 μL Buffer A (1M HEPES pH 7.9, 1M KCl, 1MMgCl2, 1M DTT, 100mM PMSF, and 10μL/mL 
each of freshly added aproptinin, leupeptin, pepstatin A protease inhibitors) and incubated on ice for 
15min. Following, 1% NP-40 was added and cells were vortexed, and then centrifuged for 5min at 
13K rpm. Supernatent (cytoplasmic fractions) were aliquoted and stored at -80ºC. Remaining pellets 
were further resuspended in 175 μL Buffer B (1M HEPES pH 7.9, 1 M MgCl2, 1M DTT, 100mM 
PMSF, 1M NacL, 20% Glycerol, and 10μL/mL each of freshly added aproptinin, leupeptin, pepstatin 
A protease inhibitors). Pellet was shaken vigorously on a rocker for 30min at 4ºC, and then 
centrifuged for 15min at 13K rpm. Supernatant (nuclear fraction) was aliquoted in pre-chilled tubes 
and stored at -80ºC for further analysis.  
 
4.1.5 Protein Assay 
Total protein content of samples was determined according to the Bradford assay, using a protein 
assay dye reagent (Bio-Rad Laboratories, Hercules, CA) and bovine serum albumin as a standard. 
Duplicates of each sample were analyzed in a 96 well plate, and absorbance measured with Bio-Rad 
3550-UV Microplate Reader at 595nm (Bio-Rad Laboratories). 
 
4.1.6 Western Blot Analyses 
Whole cell lysates and nuclear rich extracts were analyzed for protein expression by western blotting. 
Samples with consistent protein content, 10μg per sample, were mixed with equal amount of 
Laemmli 2xSDS buffer, and heated for 4min at 90ºC. Resolving gels were made with Acrylamide-Bis 
 
 46 
(30% T, 2.67% C), 1.5 M Tris-HCL (pH 8.8), 10% SDS (Fisher Scientific), 10% Ammonium 
persulphate, and 0.05% TEMED. Stacking gels were made similarly, with the exception of Tris-HCL 
buffer, which was 0.5 M with pH 6.8. The percentage of acrylamide in each gel was used according 
to the kDa weight of the protein to be detected. In addition, one molecular weight marker per gel was 
loaded to track protein separation. Proteins were then separated by Sodium Dodecyl Sulfate 
Polyacrylamide Gel Electrophoresis (SDS-PAGE) at 120V for 90min using the Mini-Protean-BioRad 
II apparatus (Bio-Rad Laboratories). Subsequently, the protein gel was placed on the top of a filter 
paper pre-soaked in transfer buffer, which was then overlaid with a 0.45μm PVDF membrane (Pall 
Corp., FL) pre-soaked in methanol for 15min. Another filter paper was placed on top to complete the 
membrane sandwich which then placed in the Trans-Blot Semi-Dry transfer cell (Bio-Rad 
Laboratories Ltd, Canada) at 20V, for 30min. Equal loading and adequate transfer was visualized by 
soaking membranes in Ponceau-S stain, followed by washing of membranes in several changes of 
dH2O (Appendix C). At this point, gels were stained with Coomassie Blue solution to ensure proper 
separation of proteins (Appendix C).  Membranes were then blocked for 1h at room temperature in 
5% skim milk powder in TBS-T and subsequently probed with primary antibody for 1h at room 
temperature, followed by overnight incubation at 4ºC. Following three times wash in TBS-T for 
10min each, blots were probed with appropriate horse radish peroxidase (HRP) or alkaline 
phosphatase (AP) conjugated secondary antibodies for 2h at room temperature, and once again 
washed in TBS-T for three washes, 10min each. Blots were incubated for 5min with SuperSignal 
West Pico Chemiluminescent substrate (Pierce) and exposed in FluorChem™ Imaging Systems 
(Alpha Innotech Corporation, CA, USA) for peroxidase conjugated antibodies. Blots probed with AP 
secondary antibody were developed with 5-Bromo-4-Chloro-Indolyl-Phosphatase/ Nitroblue 
tetrazolium (BCIP/NBT) solution, and the reaction was stopped with distilled water once bands 
became visible.  
 
Optimal amount of protein for loading was determined by performing a linear range western blot; 
increasing amount of protein was loaded in successive lanes of one gel and probed with housekeeping 
protein antibody for β-actin to determine saturation point of protein (Appendix C). All subsequent 
western blots were performed with protein amounts within the tested range. In addition, equal loading 
and constant protein expression of β-actin was determined (Appendix C). Each western blot is 




4.1.7 NF-κB Activity Assay 
Activation of NF-κB, p65 subunit, was measured in ELISA format according to manufacturer's 
protocol for the commercially available TransAM kit (Active Motif, Carlsbad, CA). Briefly, 5μg of 
nuclear or whole cell extracts in lysis buffer were loaded in wells coated with oligonucleotide with 
the 5´-GGGACTTTCC-3´ sequence recognized by active NF-κB. Incubation with primary antibody 
specific to the p65 subunit was followed by exposure to HRP-conjugated secondary antibody and 
developing solution. Absorbance was read at 450nm along with a reference at 655nm. Samples were 
tested in triplicate and expressed as mean absorbance ± SE.  
 
4.1.8 Statistical Analysis 
Statistical analyses was carried out using the t-test, or ANOVA in conjunction with Tukey post-hoc 
test, using SPSS 13.0 statistical software (Chicago, IL). For all tests, p≤0.05 was considered 
significant.  
 
4.2 Study 2: Tumor incidence and phenotype in Zk-Ob, Zk-Ln, and SD rats 
4.2.1 Animals 
Female Zk-Ob, Zk-Ln and SD rats (n=30/group) at 5 weeks of age, weighing approximately 153, 88 
and 126g respectively were obtained from Charles River (Montreal, QB). Animals were housed in 
plastic cages lined with woodchip bedding and stainless steel wire mesh lids in the Biology Animal 
Facility, with controlled environmental conditions (22ºC temperature, 50% humidity, 12hr light/dark 
photoperiod). Standard labchow (Rodent Diet 5001, Labdiet, MO, USA) and water was provided ad 
libitum. Animal care and all investigative procedures adhered to guidelines of the Office of Research 
Ethics, University of Waterloo (AUPP:04-17) and the Canadian Council of Animal Care. Body 
weights of animals were monitored bi-weekly for the initial 15 weeks of the study, and finally at 
termination.   
 
Following a 1 week acclimatization period, animals were injected subcutaneously with colon specific 
carcinogen AOM diluted in 0.9% saline at a dose of 10mg/kg body weight, once a week for two 
weeks. Animals were terminated at 30 weeks by CO2 asphyxiation. After recording body weight, 
blood was obtained in heparinized or EDTA vacutainer tubes (BD Vacutainer Systems, NJ) from a 
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cardiac puncture using a multiple sample Luer adapter. Weights of heart, liver, spleen, kidney, 
adipose and muscle tissues were recorded, and specimens were frozen for future analysis.  
4.2.2 Blood Analysis 
Blood samples were centrifuged for 10min at 2000rpm to separate plasma, which was then aliquoted. 
Samples were either stored for further analysis at -80ºC, or sent to Animal Health Laboratories 
(University of Guelph, Guelph, ON) for complete blood count (CBC) and biochemical (TG: 
triglycerides, HDL: high density lipoprotein, CK: creatinine kinase, ALT: alanine aminotransferase, 
AST: aspartate aminotransferase, CB: conjugated bilirubin, TB: total bilirubin) analysis using rat 
specific parameters. Heparinized and EDTA plasma was used for biochemical and CBC assays 
respectively.  
 
Additionally, plasma levels of insulin and leptin (Linco Research Inc., St. Charles, MS), TNF-α 
(Pierce Endogen, Rockford, IL), and sTNFR1 and sTNFR2 (R&D Systems, Minneapolis, MN) were 
assessed using commercially available sandwich enzyme linked immunosorbent assay (ELISA) kits, 
according to manufacturer’s protocol. Briefly, standards, blanks and prepared samples diluted with 
assay buffer were incubated in a 96-well plate pre-coated with antibody of interest. Wells were then 
aspirated, washed, and further incubated with conjugated antibody. Following another aspiration and 
wash step, substrate solution was added to each well, and color development was monitored and 
terminated with stop solution. Absorbance was read at 450nm with a correction reading set at 540nm 
using Asys UVM 340 spectrophotometer.  
 
A four parameter logistic curve fit was applied to the standard curve, and averages of sample 
absorbance values were compared to determine protein concentrations using GraphPad Prism 
Software (San Diego, CA). Values were multiplied with the dilution factor when applicable, and 
expressed as averages of n=8 at the least, ±SE. 
 
Plasma was further assayed for levels of o-tyrosine and 8-OH-DGnc markers of ROS, and free 3-
nitrotyrosine marker of reactive nitrogen species (RNS) at the Ottawa Health Research Institute 
(Ottawa, ON). Analyses was carried out via a novel, highly sensitive, non-radioactive HPLC method 




4.2.3 Colon Preparation 
Colon from each animal was removed, flushed with ice-cold PBS, and placed on a cold plate set at 
4ºC. A longitudinal cut was made from the rectal to the ceacal end. Colons intended for 
morphological or immunohistochemistry analyses were spread flat between two filter papers, and 
fixed in either 10% neutral buffered formalin, or Carnoy’s fixative (3:1 Ethanol and Glacial Acetic 
Acid).  Mucosa from the remaining colons was scraped separately according to proximal and distal 
regions, snap frozen in liquid nitrogen, and stored at -80ºC for biochemical analyses.  
 
4.2.4 Tumors 
Tumors were recorded for size and location from the rectal end of the colon, and either excised and 
snap-frozen in liquid nitrogen, or fixed in place in 10% neutral buffered formalin for histological 
analyses. All tumors used for analyses in this study ranged from 20-50 mm2 in size.  
 
Calculation of Tumor Parameters 
The following tumor parameters were assessed:  
 
• Tumor incidence (% of total animals with tumors/group) 
• Total number of tumors 
• Tumor multiplicity (Average number of tumors per tumor bearing rat) 
• Average tumor size (mm2)/tumor- bearing rat 
o  (Total of average size (mm2) of tumor in each tumor bearing rat/Number of tumor 
bearing rats in the group) 
• Average tumor size (mm2)/group  
o (Total size (mm2) of all tumors in the group/number of tumors in the group) 
• Tumor Burden  
o (Total of Total Tumor area in each tumor bearing rat in group/Total number of tumor 
bearing rats in the group) 
• Total Number of Microadenomas 
 
4.2.5 Sample Preparation 
Colon scrapings (from distal half of the colon) and distally located tumors (within 0-8cm of the colon, 
measured from the rectal end) were homogenized in 1mL of ice-cold RIPA buffer over an ice-bath 
using a polytron homogenizer. Samples were then rinsed with an additional 500μL of RIPA buffer 
along with 10 μL PMSF protease inhibitor. Following centrifugation for 15min at 10K RPM, and then 
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again for 5min at 15K RPM, aliquots of the supernatant were collected and stored at -80˚C. Total 
protein was quantified using the Bradford assay, as described previously (section 4.1.4).  
 
4.2.6 Western Blot Analyses  
Colon and tumor homogenates were analyzed for protein expression via western blotting techniques 
as described (section 4.1.5). Equal amount of protein, 100μg and 300μg per tumor and colon samples 
respectively, were loaded in each lane. All membranes were probed with AP conjugated secondary 
antibodies at 1:1000 dilutions, and developed with BCIP/NBT solution. As before, linear range 
westerns for colon and tumor samples were probed with β-actin to determine protein saturation points 
(Appendix C). In addition, equal loading and constant protein expression of β-actin was determined 
(Appendix C).  Densitometric analyses was carried out using AlphaEase®FC Image Analyses 
Software (Alpha Innotech). A common sample of rat liver homogenate was used in each blot to 
account for gel-to-gel variability when comparing results from two different blots. For example, each 
densitometric value of interest was adjusted to the ratio of common samples between the two blots 
under comparison. Each western blot is representative of one gel, and each band indicates a colon or 
tumor sample from one individual animal.  
 
Amount of protein loaded for colonic mucosae was three times more than tumor samples. Thus, 
densitometric data was adjusted by multiplying tumor values by three in order to present results on an 
equal protein basis when comparing between colon and tumor protein expression.    
 
4.2.7 NF-κB Activity Assay 
Measurement of active form of p65 NF-κB in colon and tumor homogenates was performed with the 
TransAM kit as described (section 4.1.7). 
  
4.2.8 Immunohistochemical Analyses 
Semi-quantitative assessment of spatial expression of specific proteins was conducted by IHC 
analyses. Selected tumors were placed in formalin and sent to Animal Health Laboratories 
(University of Guelph) for sectioning. Briefly, specimens were embedded in paraffin wax, sectioned 
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into 4-6μm thick pieces, and mounted onto slides. One section from each tumor was stained with 
hematoxylin and eosin (H&E), while the rest were processed for IHC analyses.  
 
Tumor sections were deparaffinized in xylene, and rehydrated in a series of 100%, 70%, and 50% 
ethanol, followed by several washes in dH2O. As preservation of samples in formalin often results in 
conformational changes of epitopes and subsequent loss of antibody reactivity, an antigen retrieval 
procedure using Citrate buffer (BioGenex, San Ramon, CA) was performed. Slides were submerged 
in 1X Citrate buffer and brought up to a rapid boil in a conventional microwave oven. Next, samples 
were simmered at a low power setting for an additional 4 minutes, and allowed to cool in the buffer 
for another 15-20min. Slides were rinsed with several changes of dH2O to complete antigen retrieval 
procedure. 
 
Samples were then incubated in 3% H2O2 to quench any endogenous peroxidase activity, rinsed with 
dH2O, and then dipped in 2N HCl for 30sec, followed by additional washes in dH2O. Blocking serum 
from Rabbit Histostain® Bulk Kit (Zymed Laboratories, San Francisco, CA) was added to completely 
cover the tissue, and slides were incubated in a humid chamber at ambient temperature for 20min. 
Subsequently, primary antibodies for TNF-α, TNFR1, TNFR2, NF-κB, and IκBα were prepared in 
dH2O at a dilution of 1:200, applied to labeled sections, and incubated for 2 hours in the humid 
chamber. Sections were then rinsed in dH2O and incubated for an additional 30min with biotinylated 
secondary antibody (linking reagent), followed by incubation with an enzyme conjugate (labeling 
reagent) for 10min.The 3,3-diaminobenzidine tetrahydrochloride (DAB) chromagen was prepared 
using a DAB substrate kit (Zymed) and applied to sections to initiate peroxidase reaction. Upon 
visualizing color formation, slides were washed several times in dH2O and counterstained with 
Hematoxylin. Following sequential dehydration of section in ethanol, slides were immersed in xylene 
and mounted with glass coverslips using Permount. Control slides with either no primary or 
secondary antibodies were included in the analyses to ensure specificity of the reaction (Appendix C). 
4.2.9 Statistical Analysis 
Statistical analyses was carried out using ANOVA in conjunction with Tukey and LSD post-hoc tests 
where appropriate, using SPSS 13.0 statistical software (Chicago, IL). For all tests, p≤0.05 was 
considered significant.  
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4.3 Study 3: Differences in protein expression patterns in distal and proximal tumors 
of Zk-Ob rats 
 
Tumors were procured as described previously (section 4.2.4) and selected for protein analyses based 
upon their location. Specifically, distal and proximal tumors located at 0-8cm and 8-16cm from the 
rectal end respectively were chosen from Zk-Ob rats. 
4.3.1 Sample Preparation 
Tumors were homogenized in 1mL of ice-cold RIPA buffer over an ice-bath using a polytron 
homogenizer. Samples were then rinsed with an additional 500μL of RIPA buffer along with 10 μL 
PMSF protease inhibitor. Following centrifugation for 15min at 10K RPM, and then again for 5min at 
15K RPM, aliquots of the supernatant were collected and stored at -80˚C. Total protein was 
quantified using the Bradford assay, as described previously (section 4.1.4).  
 
4.3.2 Western Blot Analyses  
Tumor homogenates were analyzed for protein expression via western blotting techniques as 
described (section 4.1.5). Equal amount of protein, 100μg per sample, were loaded in each lane. All 
membranes were probed with AP conjugated secondary antibodies at 1:1000 dilutions, and developed 
with BCIP/NBT solution. Densitometric analyses was carried out using AlphaEase®FC Image 
Analyses Software (Alpha Innotech). In addition, equal loading and constant protein expression of β-
actin was determined (Appendix C). A common sample of rat liver homogenate was used in each blot 
to account for gel-to-gel variability when comparing results from two different blots. For example, 
each densitometry value was adjusted to the ratio of common samples between the two gels under 
comparison. Each western blot is representative of one gel, and each band indicates a tumor sample 
from one individual animal. 
 
4.3.3 Statistical Analysis 
Statistical analyses was carried out via the t-test, using SPSS 13.0 statistical software (Chicago, IL). 






Study 1:Effects of TNF-α and NF-κB inhibitors on HT-29 colon cancer cells  
5.1 Study Background and Objectives 
Cell culture model systems are a valuable tool for providing insight into disease mechanisms and 
identifying potential chemopreventative agents. HT-29 colon adenocarcinoma cells have been shown 
to be relatively resistant to TNF-α mediated apoptosis in comparison to other colon cancer cell lines. 
Thus, they are ideal to investigate the interaction between TNF-α and NF-κB pathways with regards 
to cell survival signaling.  
 
The central theme of this thesis project is that tumorigenesis noted in Zk-Ob rats is due to the ability 
of preneoplastic lesions, and therefore tumors, to resist the pro-apoptotic effects of TNF-α. In order to 
test this hypothesis, it was essential to determine the changes associated with the TNF-α resistant 
phenotype from cellular and molecular perspectives. Thus, Study 1 utilized HT-29 cells that exhibit 
resistance to TNF-α mediated cytotoxicity to further investigate responses to exogenous TNF-α 
treatment, and involvement of NF-κB, which is known to transcribe survival genes.  
 
General objectives of this study were to:  
 
• acquire experience with experimental techniques  
• assess the treatment effect of TNF-α and NF-κB inhibitors on HT-29 colon cancer cells 
 
In the present study, HT-29 cells were exposed to TNF-α, and alterations in protein levels of key 
players in TNF-α and NF-κB pathways were assessed by western blot. In addition, active form of NF-
κB was assessed in the nuclear rich fractions of HT-29 cells.  
 
To assess the involvement of NF-κB in rendering protection against TNF-α mediated cytotoxicity, 
cells were treated with NF-κB inhibitors. Hypericin has been shown to block NF-κB via proteosome 
inhibition of the IκB subunit, making SJW an ideal candidate. Thus, two novel, chemically 
standardized SJW whole-plant extracts with optimized chemical profiles for either hypericin or 
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hyperforin content were utilized (Plant Cell Technology Lab, University of Guelph). Commercially 
available hypericin and hyperforin standards were used as an additional comparison.  
 
Specific aims of this study were: 
 
• To determine changes at protein levels of TNFR1, TNFR2, NF-κB, IκBα, and IKKβ in HT-
29 cells treated to exogenous TNF-α.  
• To assess whether inhibition of NF-κB via SJW extracts and standards augment TNF-α 
mediated cytotoxicity in otherwise resistant HT-29 cells. 
 
5.2 Results 
5.2.1 Methodological Approach 
Details of experimental procedures are provided in Chapter 4 Materials and Methods. Briefly, HT-29 
cells were grown and treated with TNF-α and/or SJW extracts and standards upon confluency. 
Treatment effects were assessed by MTT cytotoxicity assay, and morphological analyses via EtBr and 
AO staining. Cells were processed for whole cell and nuclear rich fractions, and levels of specific 
proteins of interest were determined by western blot. Active levels of p65 NF-κB were further 
evaluated by the TransAM kit.    
 
5.2.2 Cytotoxicity Assay 
 
HT-29 cells exhibit cytotoxic resistance to TNF-α treatment, but not SJW  
In order to confirm the resistant phenotype of HT-29 cells towards TNF-α mediated cytotoxicity, cells 
were treated with increasing concentrations of TNF-α, and viability was assessed with MTT assay. 
Results indicated the percentage of cell survival to fluctuate around 100%, while 50% survival was 
observed at the highest concentration of 100ng/mL (Figure 5-1A). Toxicity resulting from extremely 





Conversely, treatments of SJW extracts, HYex, HPex and standards HP and HY resulted in dose 
dependant cytotoxic responses at 24 and 48h (Figure 5-1B). LD50 doses for HY and HP were ~7.5 μM 
and 10μM respectively, while those for HYex and HPex were ~10μL/mL.  
 
HPLC analyses of extracts confirmed total amount of active constituent of HY and HP present (data 
provided by University of Guelph). Relative amounts of HY and HP constituents in both extracts 
were compared to amounts of HY and HP in commercially available standards, using LD50 values 
from the MTT assay as a reference point (Appendix C). 
 
Combination treatment of TNF-α and SJW sensitizes HT-29 cells to cytotoxic response  
Cells were treated to dosages of SJW compounds that were previously seen to have low toxicity via 
MTT assay in combination with a constant concentration of 10ng/mL of TNF-α. Combination 
treatments had significantly more cytotoxicity than standard, extract, or TNF-α by itself, indicating a 



























































































































Figure 5-1: Effects of (A) TNF-α and (B) SJW extracts and standards on cell viability of HT-29 
cells. 
HT-29 cells were seeded in 96 well plates, and treated upon confluency with increasing 
concentrations of TNF-α for 24, 48, and 72h, or HYex, HPex, HY, and HP for 24 and 48h in fresh 
serum-free media. Following treatment periods, cells were incubated with MTT for 5h, and purple 
formazen crystal formation was measured at 570nm. Results are expressed as percentage of the 
control and indicate mean of triplicates ± SE from at least three independent experiments. HY: 


















































































































Figure 5-2: Combination treatment effects of TNF-α and SJW extracts and standards. 
HT-29 seeded in 96 well plates were treated with either TNF-α (10ng/mL), HYex, HPex (2.5μL/mL), 
HY,HP (2μM), or in combination of each individual SJW compound with TNF-α for 24 and 48h. 
Following treatment periods, cells were incubated with MTT for 5h, and purple formazen crystal 
formation was measured at 570nm. Results indicate mean of triplicates ± SE. from at least three 
independent experiments. Values with different superscripts are significantly different via t-test, 





5.2.3 Morphological Analyses 
 
Cells treated with TNF-α and SJW were stained with a combination of AO and EtBr dyes. AO 
fluoresces green and stains both live and dead cells, while also fluorescing orange when binding with 
RNA. In contrast, EtBr fluoresces red/orange and only penetrates cells with compromised 
membranes. Depending on the degree of dye penetration, cells will stain from yellow, to orange and 
red in color, giving an indication of cellular integrity (Figure 5-3).  
 
Control and TNF-α treatment (Figure 5-3:A1,A2) show a healthy population of cells with organized 
structure, and intact membranes and nuclei. Overall, cells treated with just extract or standards at low 
concentrations (Figure 5-3:B1,C1,D1,E1) have fewer necrotic and apoptotic cells (with an exception 
of HY treatment, D1, showing cell shrinkage and extensive necrosis) in comparison to cells exposed 






















Figure 5-3: EtBr and AO staining of treated HT-29 cells treated with TNF-α and/or SJW 
(200x). 
HT-29 cells were seeded in 6-well plates and treated at confluency with either 2.5 μL/mL HPex, 
HYex, or 2μM HP and HY, or each treatment in combination with 10ng/mL TNF-α for 24h. 
Following, cells were incubated with a combined stain of EtBr and AO, and viewed under a blue light 
filter. A1:control, A2: TNF-α, B1: HYex, B2: HYex+TNF-α, C1: HPex, C2: HPex+TNF-α, D1: HY, 
D2: HY+TNF-α, E1:HP, E2:HP+TNF-α. Arrows indicate distinct necrotic and apoptotic cells with 




























    
    
     
     















5.2.4 Western Blot Analyses 
 
TNF-α stimulates, while SJW inhibits NF-κB protein expression  
Western blots of HT-29 cells treated with increasing concentrations of TNF-α, as well as two 
concentrations each of SJW standards and extracts showed conflicting patterns of NF-κB expression 
(Figure 5-4). Higher levels of NF-κB were seen in both whole cell and nuclear rich fractions (used to 
determine levels of potentially active NF-κB) from cells treated with TNF-α, while inhibitory action 
was demonstrated by SJW. Among the standards however, HP appeared to stimulate NF-κB in 
comparison to the strong inhibitory effect of HY, a known NF-κB blocker. In contrast to HP, HPex 
did inhibit NF-κB, demonstrating a difference between standard and extract treatment.  
 
Synergistic effects of SJW and TNF-α on NF-κB expression  
Cells treated with combinations of TNF-α and SJW compounds were analyzed for changes in NF-κB 
levels (Figure 5-5). Similar patterns were observed between whole cell and nuclear rich fractions. 
Combination treatments inhibited NF-κB expression in comparison to TNF-α or SJW exposure alone. 
In contrast to HPex, the HP standard, with or without TNF-α had no detectable effect on NF-κB level. 
Additionally, HYex was observed to have a stronger effect than HPex.  
 
Treatment effects on active NF-κB levels  
Active p65 NF-κB levels in nuclear rich lysates was measured using the TransAM transcription factor 
ELISA kit (Figure 5-6). A significant increase in active NF-κB from 5 to 10ng/mL TNF-α treatment 
was detected. The combination of TNF-α and SJW showed a decrease in active form in comparison to 
individual treatments. HP on its own, or in combination with TNF-α did not cause a significant 
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Figure 5-4: Individual effects of TNF-α and SJW on NF-κB protein expression. 
Western blots of cells treated with A:TNF-α (5, 10, and 30ng/mL), or B:HYex, HPex (10 and 
15μL/mL) and HY, HP (5, 10μM) for a 24h treatment period are shown. Whole cell or nuclear 
lysates, 10μg of protein per sample, were processed and separated through SDS-PAGE. Following 
transfer, membranes were probed with primary antibody for p65 NF-κB, followed by rabbit HRP-
conjugated secondary antibody, and exposed in FluorChem™ imager. HY: hypericin, HYex: 



































Figure 5-5: Synergistic effects of TNF-α and SJW treatment on NF-κB expression. 
Western blots of cells treated with HPex, HYex (2.5 μL/mL), or HP, HY (2μM), as well as in 
combination with 10ng/mL TNF-α for 24h are shown. Whole cell and nuclear rich lysates, 10μg of 
protein per sample, were processed and separated by SDS-PAGE. Following transfer, membranes 
were incubated with primary antibody for p65 NF-κB followed by rabbit HRP conjugated secondary 
antibody, and exposed in FluorChem™ imager. HY: hypericin, HYex: hypericin extract, HP: 
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Figure 5-6: Measurement of active NF-κB levels in nuclear rich extracts of TNF-α and SJW 
treated cells. 
Nuclear rich lysates were extracted from cells treated with 5, 10, and 30ng/mL TNF-α (A), 2.5 μL/mL 
HPex, HYex, (B), or 2μM HP and HY (C), with each SJW compound also combined with 10ng/mL 
TNF-α for 24h. Active levels of p65 NF-κB were measured by a transcription factor ELISA (Active 
Motif) by loading nuclear rich extracts, 2 μg of protein per sample, in a 96 well plate coated with 5´-
GGGACTTTCC-3´ oligonucleotide sequence. Incubation with primary antibody specific to the p65 
NF-κB subunit was followed by exposure to HRP-conjugated secondary antibody and developing 
solution. Absorbance was read at 450nm along with a reference at 655nm. Samples were tested in 
triplicate and expressed as percentage of control (untreated cells) means ± SE. Values with different 
superscripts are significantly different via ANOVA in conjunction with Tukey post-hoc test, p<0.05. 
HY: hypericin, HYex: hypericin extract, HP: hyperforin, HPex: hyperforin extract.  
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Treatment effects of SJW and TNF-α on protein expression of key players in of TNF-α/ NF-κB 
pathways  
Whole cell extracts treated with TNF-α and SJW were analyzed for changes in expression of TNFR1, 
TNFR2, IκBα, and IKKβ proteins. With increasing concentrations of TNF-α treatment, TNFR2 and 
IKKβ were upregulated, while TNFR1 and IκBα protein expression decreased (Figure 5-7A). Cells 
treated with both SJW and TNF-α resulted in a significant reduction of IκBα and IKKβ (Figure 5-7B). 
Additionally, combination treatments appeared to downregulate TNFR2, and upregulate TNFR1, 











































































Figure 5-7: Treatment effects of TNF-α and SJW on TNFR1, TNFR2, IκBα, and IKKβ protein 
expression. 
Western blots of cells were treated with A: TNF-α (5, 10, and 30ng/mL) or B: HPex, HYex (2.5 
μL/mL), or HP, HY (2μM), as well as in combination with 10ng/mL TNF-α for 24h are shown. 
Following extraction, 10 μg of protein per sample was loaded, separated with SDS-PAGE, and 
transferred on membranes for immunoblotting. Following incubation with primary antibodies to 
TNFR1, TNFR2, IκBα and IKKβ membranes were exposed to corresponding AP conjugated 
secondary antibodies and developed with BCIP/NBT solution. HY: hypericin, HYex: hypericin 





The dual nature of TNF-α and NF-κB pathways in mediating cell death and survival signals pose 
many questions as to their involvement during carcinogenesis. Preneoplastic lesions and tumors have 
been shown to exhibit resistance to TNF-α mediated cell death. To better understand this response 
from a cellular and mechanistic approach, HT-29 cells otherwise resistant to cytotoxicity by TNF-α, 
were treated with this cytokine, and expression of key proteins was analyzed. As NF-κB is thought to 
contribute to this resistant phenotype by initiating a survival signal, protein levels relevant to the NF-
κB pathway were also examined. Subsequently, inhibition of NF-κB by SJW treatments were 
investigated to further study potential effects on survival outcome.  
 
TNF-α pathway modulation  
 
TNF-α exerted little to no cytotoxicity to HT-29 cells. A relative increase in expression of NF-κB 
upon TNF-α treatment indicated its involvement in mediating cell survival. Moreover, levels of active 
p65 NF-κB in nuclear rich fractions also increased with exposure to TNF-α. There is a strong 
possibility therefore, that the amplified activity of NF-κB led to transcription of survival proteins 
counteracting the potential apoptotic effects of TNF-α. IKKβ is responsible for releasing NF-κB from 
its inhibitor subunit IκBα and initiating its migration to the nucleus for transcription. Higher and 
lower levels of IKKβ and IκBα proteins respectively supported the contention that this pathway was 
activated in HT-29 cells in response to exogenous TNF-α.  
 
The expression patterns of these key proteins identify the NF-κB pathway as critical in the survival 
response in HT-29 cells, possibly contributing to its resistant phenotype towards TNF-α. To further 
substantiate these conclusions, it would be important to look at expression patterns of survival 
proteins associated with NF-κB transcriptional activity. 
 
Downstream signaling mediated by TNFR1 and TNFR2 is complex, and not yet fully explored. 
TNFR1 is generally recognized to contribute to death signals whereas TNFR2 favors a survival signal 
(Higuchi and Aggarwal 1994b). In this study, upregulation of TNFR2 and inhibition of TNFR1 in 
HT-29 cells was observed upon treatment of TNF-α. It may be speculated that receptor modulation is 
also a contributing factor for resistance of HT-29 cells towards TNF-α mediated cytotoxicity. 
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Although TNFR2 can also play a role in death signaling, there seems to be preferential tendency 
towards the survival outcome in the presence of exogenous TNF-α.   
  
NF-κB inhibition sensitizes HT-29 cells to TNF-α mediated cell death 
 
The role of SJW as a NF-κB inhibitor was confirmed by the decreasing levels of protein in whole cell 
and nuclear rich fractions of treated cells. While components of SJW have been shown to 
independently induce apoptosis through various mechanisms such as caspase cleavage (Hostanska et 
al. 2003), the correlation of protein expression patterns and cytotoxicity assays indicate NF-κB 
inhibition to also play a role in mediating cell death.  
 
The combination of TNF-α and SJW significantly increased the cytotoxic response, as determined by 
MTT assay as well as morphological analyses demonstrating higher numbers of necrotic and 
apoptotic cells. Since this occurred with low doses of SJW that were otherwise non-toxic to HT-29 
cells, it may be speculated that this response was due to synergistic activity of the treatments, and not 
SJW alone. Lower levels of NF-κB p65 subunit determined by western blot and NF-κB activation 
assay suggest that downregulation of NF-κB plays a role in augmenting a cell death signal. 
Biologically, TNF-α could stimulate both cell death and survival. Inhibition of NF-κB via SJW 
appears to augment TNF-α mediated cell death and a subsequent switch in downstream signaling in 
the presence of exogenous cytokine. Thus, in circumstances where resistance to TNF-α is seen, as 
with HT-29 cells, the strategy of NF-κB inhibition holds potential for achieving the desired outcome 
of cell death.   
 
Evidence that NF-κB pathway is being downregulated by the combination treatment is substantiated 
by the decrease in IKKβ level. However, expression of IκBα was virtually non-existent in the cell 
extracts, and was opposite to what was expected. It is possible that low expression of IκBα was due to 
proteosomal degradation, or a decrease in its transcription by lower levels of active NF-κB. It would 
be pertinent to analyze IκBα expression in nuclear fractions as IκBα can also enter the nucleus and 
bind NF-κB, inhibiting its activity.  
 
Combination treatments of SJW and TNF-α resulted in higher and lower expression of TNFR1 and 
TNFR2 respectively, opposite trends seen from TNF-α exposure alone. As discussed, TNFR appear to 
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play differential roles in cell death signaling, and their expression may be modulated by the cell to 
achieve a desired outcome. Upregulation of TNFR1 in combination with NF-κB inhibition presents a 
mechanism by which the two TNF-α and NF-κB pathways are oriented towards cell death outcome.  
 
Questions that remained unanswered in this study include how NF-κB promotes cell survival in HT-
29 cells upon treatment with TNF-α. Further study into transcription of survival proteins is warranted. 
Moreover, substantial evidence exists for the pro-apoptotic effects of NF-κB, and it would be 
interesting to investigate how this aspect would come into play in the proposed mechanisms.  
 
Due to its extensive role in promoting carcinogenesis, NF-κB inhibition is a popular strategy from 
treatment perspectives (Perkins and Gilmore, 2006). As seen by this study, inhibition of NF-κB via 
SJW increases cytotoxicity on its own, and augments the cell death signal initiated by TNF-α in cells 
that otherwise exhibit resistance. However, the multiple effects of NF-κB and interplays with other 
signaling pathways are reasons to approach the inhibition strategy with caution. Considering the 
inherent duality of NF-κB itself, blocking it may also weaken the pro-apoptotic responses, and 
potentially promote tumor growth (Kim et al. 2006). Thus, careful consideration must be given to the 
interaction between cancer therapies and NF-κB activity, and its subsequent effects on downstream 
signaling.   
 
Most importantly, these findings confirmed that the ability of HT-29 cells to resist TNF-α induced 






Study 2: Tumor incidence and phenotype in Zk-Ob, Zk-Ln, and SD rats  
6.1 Study Background and Objectives 
Obesity associated pathological abnormalities such as high levels of plasma insulin and lipids are 
coined as the metabolic syndrome, and are considered a key link with many other physiological 
disorders such as cancer, diabetes, and cardiovascular disease (Shaw et al. 2005, Sorrentino 2005).   
 
The TNF-α and NF-κB pathways are observed to play significant roles in the manifestation of obesity 
and metabolic syndrome. High levels of adipokines such as TNF-α produced by adipocytes mediate 
insulin resistance, and stimulate leptin production, among other hormones. TNF-α also contributes to 
a pro-inflammatory environment by initiating ROS and RNS production leading to oxidative stress 
(Sonnenberg et al. 2004). Activation of NF-κB by TNF-α further contributes metabolic disorder and 
cell cycle disturbance via transcription of survival proteins. Insulin resistance and oxidative stress are 
few of the consequences of NF-κB activation, establishing a central role of this transcription factor in 
the manifestation of metabolic syndrome (Gunter and Leitzmann 2006, Sonnenberg et al. 2004).  
 
Unlike the epidemiological associations, the mechanistic link between obesity and cancer is still 
under investigation. Both TNF-α and NF-κB pathways, which are also significant for metabolic 
disorders, play controversial roles in carcinogenesis. Genes transcribed by NF-κB have multiple 
functions, leading to apoptosis or survival. Physiologically elevated TNF-α could induce cell death, 
whereas in the same organism it is suggested that neoplastic tissue could take advantage of TNF-α 
activated NF-κB for growth. At present, very little is known how elevated TNF-α affects tumor 
phenotype.  
 
Zk-Ob rats are an ideal model system for this investigation due to their inherent characteristics of 
metabolic dysregulation and elevated levels of plasma TNF-α. Previous studies found Zk-Ob rats to 
have an increased number of ACF in comparison to their lean counterparts, along with higher plasma 
levels of insulin, cholesterol, triglycerides, and lactate (Raju and Bird, 2003). In addition to ACF, 
higher incidence of adenocarcinomas in Zk-Ob versus Zk-Ln rats is also reported (Weber et al. 2000). 
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Furthermore, hyperinsulinaemia in these animals is observed to be strongly associated with colon 
cancer incidence (Lee et al. 2001). In this study, Zk-Ob rats, along with their lean counterparts, Zk-Ln 
rats, were used a model system. In addition, SD rats were used concurrently as an external 
comparison to the Zucker strain. It was thereby possible to determine if the differences in tumor 
outcome noted between Zk-Ob and Zk-Ln rats was not simply because Zk-Ln rats were resistant to 
colon carcinogenesis due to their genotype.  
 
The primary objective of this study was: 
To determine if tumors appearing in Zk-Ob rats are biologically different from those in Zk-Ln 
and SD rats. It is hypothesized that the physiological state of Zk-Ob rats will affect tumor 
phenotype. In particular, elevated levels of TNF-α in these animals exerts a tumor promoting 
effect by inducing increased expression of transcriptionally active NF-κB, which is known to 
transcribe genes crucial to cell survival.  
 
In order to accomplish this objective, this study was divided into three components with the following 
aims:  
 
Study 2A: Assessment of physiological, hematological, and biochemical parameters in Zk-Ob, 
Zk-Ln, and SD rats 
 
Specific aims of this study were to determine effects of genotype of Zk-Ob, Zk-Ln, and SD rats on:  
• Body and organ weights 
• Complete blood count 
• Plasma levels of TG, HDL, Cholesterol, Glucose, insulin, leptin, TNF-α, sTNFR1, and 
sTNFR2 
• Plasma levels of oxidative stress markers 
 
Study 2B: Assessment of tumor parameters in Zk-Ob, Zk-Ln, and SD rats  
Specific aims of this study were to determine effects of genotype of Zk-Ob, Zk-Ln, and SD rats on:  
• Tumor incidence, multiplicity, and distribution pattern along the colonic axis   
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Study 2C: Assessment of protein expression patterns in tumors and colonic mucosa of Zk-Ob, 
Zk-Ln, and SD rats 
Specific aims of this study were to determine effect of genotype of Zk-Ob, Zk-Ln, and SD animals on 
tumors and colonic mucosae protein expression of the following: 
• TNF-α, TNFR1, and TNFR2 
• NF-κB, IκBα, and IKKβ 
• IRα, IRβ, and IGF-IRα 
• MAPK p42/p44 
 
Results and discussion of study 2A, 2B, and 2C are presented together in the following sections. A 
general discussion highlighting and integrating main findings from all studies is included in the 
conclusion, page 122.   
6.2 Results and Discussion, Study 2A: Assessment of physiological, hematological, 
and biochemical parameters in Zk-Ob, Zk-Ln, and SD rats 
6.2.1 Methodological Approach  
Details of experimental procedures are provided in Chapter 4 Materials and Methods. Briefly, Zk-Ob, 
Zk-Ln, and SD rats were designated as controls, or injected with AOM, and terminated after 30 
weeks. Body and organ weights were recorded. Blood samples were collected and processed to 
determine CBC and biochemical parameters by automated procedures. Plasma was also analyzed for 
TNF-α, insulin, leptin, sTNFR1 and sTNFR2 by ELISA, as well as oxidative stress markers by 
HPLC.  
6.2.2 Body and Organ Weights  
Body and organ weights collected from animals terminated at 30 weeks are shown in Table 6-1. As 
expected, Zk-Ob animals had higher body and organ weights in comparison to Zk-Ln and SD rats. 
Overall, AOM injected animals had lower body and organ weights than their respective controls, 
possibly due to a decreased food intake related to presence of tumors. An exception was noted, 
however, with the spleen weight of injected Zk-Ob animals, which was significantly higher than the 
control group. Splenomegaly, an enlarged spleen, indicates an over-worked, diseased state of the 
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organ corresponding to increased production of immune cells (Moore and Dalley 1999). Possibly, a 
hyperfunctional immune system in these animals was responding to the presence of tumors. This 
notable difference was only present in Zk-Ob rats, perhaps due to their increased sensitivity to 





































Table 6-1: Final body and organ weights of control and AOM injected Zk-Ob, Zk-Ln and SD     
animalsa. 
aZk-Ob, Zk-Ln, and SD animals were designated as control or injected with 10mg/kg body weight 
AOM, once a week for two weeks. Following 30 weeks, animals were terminated by CO2 
asphyxiation, and body and organ weights collected. Values expressed as mean ± SE, with at least 
n=10 per group. Values in a row without a common superscript(w,x,y,z) are significantly different, 
p<0.05 as determined by ANOVA analyses with LSD and Tukey post hoc tests. AOM: 
azoxymethane, Zk-Ob: Zucker obese, Zk-Ln: Zucker lean, SD: Sprague dawley, subscript c indicates 









 Zk-Obc Zk-Lnc SDc Zk-Ob Zk-Ln SD 
Body Weight (g) 706.3±4.3x 322.1±5.9y 473.4±18.5w 672.0±15.4x 280.9±8.3y 397.8±9.2z 
Liver Weight (g) 34.2±4.6x 13.4±0.8w 19.5±1.9xy 29.9±1.7x 10.9±0.5z 16.8±0.6y 
Heart Weight (g) 5.0±0.5x 3.5±0.2y 3.2±0.3y 3.5±0.3y 2.8±0.2y 3.3±0.1y 
Kidney Weight (g) 4.7±0.9x 3.2±0.3x 3.0±0.1y 4.3±0.6x 2.6±0.1y 2.8±0.1y 
Spleen Weight (g) 0.83±0.09x 0.58±0.05y 0.70±0.04x 1.30±0.4w 0.49±0.03y 0.69±0.03xy 
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6.2.3 Hematological Analyses 
CBC analyses was performed on blood samples collected upon termination (Table 6-2), and 
descriptions of parameter tests are included in Appendix B. Notable differences were seen in the 
WBC, segregated neutrophil, and monocyte count for Zk-Ob rats in comparison to Zk-Ln and SD, 
and were significantly higher in the AOM injected Zk-Ob group. The WBC accounts for different 
types of white blood cells, including neutrophils (immature band cells, and mature segregated 
neutrophils) T-type and B-type lymphocytes, monocytes, eosinophils, and basophils. Increased levels 
of these cell types indicate a hyperfunctional immune response, possibly due to presence of tumors in 
these animals. This observation further correlates with the significantly enlarged spleen in injected 
Zk-Ob animals. 
 
The individual monocyte count was significantly higher in AOM injected Zk-Ob rats than the control 
group. Monocytes also have a critical role in the immune response, and develop into macrophages 
upon entering tissues where they ingest foreign particles through phagocytosis (Goldsby et al. 2003). 
Monocytosis, excess monocytes in the blood, is indicative of diseased states such as chronic 
inflammation and stress responses, physiological aberrations also characteristic of Zk-Ob rats. As 
with the elevated WBC, monocytosis in these animals may be acting in response to tumors. 
Moreover, elevated monocytes may also correspond to an increased number of macrophages, primary 
secretors of TNF-α, and further contribute to inflammation, oxidative stress, and tumor promotion.  
 
With regards to red blood cells, the RBC and Hb levels were lower in injected Zk-Ob animals versus 
their control group. Conversely, both control and injected Zk-Ob rats had significantly higher RDW 
percentages, indicating an increased size of red blood cells. This may be due to a compensation for 
the lower number of red blood cells. The spleen also filters, recycles, and stores blood (Moore and 
Dalley 1999). Thus, the abnormal size of red blood cells may have further contributed to the 
splenomegaly in these animals.  
 
Interestingly, the platelet count in Zk-Ob animals was noticeably high, and even more so in the AOM 
injected group. Involved in blood clotting, platelets also secrete many growth factors and are 
physiologically linked to chronic illnesses such as cancer, heart disease, and inflammation (Adam et 





Table 6-2: Complete blood count analyses of control and AOM injected Zk-Ob, Zk-Ln and SD 
animalsa. 
 
aBlood samples were collected at termination of 30 week old control and AOM injected Zk-Ob, Zk-
Ln, and SD animals. CBC was analyzed by automated procedures, where RBC: red blood cell count, 
Hb: hemoglobin, HCT: hematocrit, RDW: red cell distribution width, MCH: mean corpuscular 
hemoglobin, MCHC: mean corpuscular hemoglobin concentration, MCV: mean corpuscular volume. 
Values expressed as mean ± SE, with at least n=8 per group. Values in a row without a common 
superscript (v,w,x,y,z) are significantly different, p<0.05, as determined by ANOVA analyses with LSD 
and Tukey post hoc tests. AOM: azoxymethane, Zk-Ob: Zucker obese, Zk-Ln: Zucker lean, SD: 
Sprague dawley, subscript c indicates control animals.  
 
 
 Zk-Obc Zk-Lnc SDc Zk-Ob Zk-Ln SD 
RBC (1012/L) 7.5±0.2x 7.5±0.4x 6.8±0.2y 6.2±0.4y 7.6±0.3x 7.1±0.1x 
Hb (g/L) 132.3±3.8x 135.4±4.1x 129.8±3.9x 111.5±4.3y 129.9±3.4x 132.8±1.9x 
HCT (L/L) 0.4±0.04x 0.4±0.04x 0.4±0.01x 0.4±0.03x 0.4±0.01x 0.4±0.01x 
Platelets (109/L) 914.0±4.6x 799.4±65.7y 691.6±65.9z 1107.0±56.5v 689.9±75.6z 547.0±86.8w
RDW (%) 15.4±0.3x 13.4±0.3y 12.7±0.2y 15.9±0.5x 12.8±0.2y 12.7±0.2y 
MCH (pg) 17.7±0.9xy 18.2±1.0xy 19.6±0.4x 18.4±0.6xy 17.9±0.5y 18.6±0.2xy 
MCHC (g/L) 341.7±12.5x 351.0±24.2x 345.0±4.2x 323.4±9.2x 322.6±2.3x 331.3±1.8x 
MCV (fL) 52.3±0.3x 50.2±1.2x 56.0±0.7y 56.1±0.1y 53.8±1.8y 56.5±0.5y 
WBC (109/L) 7.2±0.6x 6.0±1.1y 7.6±0.4x 9.4±0.4w 6.3±0.6y 9.0±0.9w 
Segregated 
Neutrophils (109/L) 
2.7±0.5x 1.7±0.5x 1.8±0.2x 4.8±0.3y 2.4±0.3x 1.8±0.2x 
Lymphocytes (109/L) 3.8±0.2y 3.8±0.8y 5.5±0.3x 3.7±0.3y 3.4±0.4y 6.6±0.8z 
Monocytes (109/L) 0.41±0.07y 0.2±0.03x 0.3±0.04x 0.6±0.04z 0.2±0.04x 0.3±0.03x 
Eosinophils (109/L) 0.3±0.1x 0.2±0.04x 0.2±0.009x 0.3±0.08x 0.2±0.05x 0.2±0.03x 
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6.2.4 Clinical and biochemical assessments 
Plasma was isolated by centrifugation of blood samples, and analyzed for key biochemical parameters 
(Table 6-3) described in detail in Appendix B. As expected, Zk-Ob animals had higher TG and 
cholesterol levels in comparison to other groups. LDL levels could not be calculated due to 
abnormally high cholesterol and triglyceride levels. Glucose levels were notably higher in AOM 
injected Zk-Ob animals versus control. Zk-Ob rats have inherent hyperinsulinemia and insulin 
resistance, and presence of preneoplastic lesions and tumors may further contribute to the elevated 
glucose levels (Komninou et al. 2003). Variable differences were seen with kidney and liver function 
assays, and no consistent trend was apparent (Appendix C). 
 
Plasma insulin, leptin, and TNF-α were determined using commercially available ELISA kits (Figure 
6-1). Zk-Ob animals had significantly higher levels of insulin and leptin than the SD rats, which were 
subsequently higher than the Zk-Ln group. No differences were seen between control and AOM 
injected groups of each strain. Most changes in response to experimentally induced cancer occur in 
early stages, possible explaining the marginal differences between control and AOM groups. The 
notably high insulin levels in Zk-Ob rats may be further connected with the high glucose levels 
observed in Table 6-2, both of which contribute to insulin resistance in these animals. Dysregulation 
of the insulin pathway is shown to intricately promote carcinogenesis (Gunter and Leitzmann 2006). 
 
Zk-Ob rats had significantly higher plasma TNF-α level than Zk-Ln and SD groups, and AOM 
injected Zk-Ob rats had higher levels than corresponding control animals.  TNF-α has rapid clearance 
from plasma (Keith et al. 2000), thus the elevated levels in Zk-Ob rat plasma may be attributed to 
continuous cytokine production by adipocytes, macrophages and tumor cells among other potential 
sources. It is well established that high levels of TNF-α are associated with both cancer and obesity, 











Table 6-3: Biochemical analyses of plasma samples collected from control and AOM injected 
Zk-Ob, Zk-Ln and SD animalsa. 
 Zk-Obc Zk-Lnc SDc Zk-Ob Zk-Ln SD 
TG (mmol/L) 24.6±2.0x 12.2±5.2y 11.±2.6y 10.5±4.2y 4.9±0.9z 6.4±1.2y 
HDL (mmol/L) 3.6±0.8x 2.2±5.2y 2.6±0.4x 4.2±0.5x 2.7±0.2y 2.7±0.2y 
Cholesterol (mmol/L) 8.7±0.5x 4.4±0.8y 4.5±0.2y 7.1±0.9x 4.2±0.5y 3.9±0.3y 
Glucose (mmol/L) 13.1±1.3x 12.2±2.5x 12.6±0.4x 16.8±1.6y 8.9±1.9z 11.1±0.6x 
aPlasma was isolated from heparinized blood samples collected at termination of 30 week old control 
and AOM injected Zk-Ob, Zk-Ln, and SD animals. Biochemical parameters were tested by automated 
procedures, where TG: triglycerides, HDL: high density lipoprotein. Values expressed as mean ± SE, 
with at least n=8 per group. Values in a row without a common superscript (w,x,y,z) are significantly 
different, p<0.05, as determined by ANOVA analyses with LSD and Tukey post hoc tests. AOM: 
azoxymethane, Zk-Ob: Zucker obese, Zk-Ln: Zucker lean, SD: Sprague dawley, subscript c indicates 
control animals.  
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Figure 6-1: Plasma levels of (A) insulin, (B) leptin, and (C) TNF-α in control and AOM injected 
Zk-Ob, Zk-Ln, and SD rats. 
Briefly, plasma samples were incubated in a 96 well plate pre-coated with antibody to insulin, leptin, 
or TNF-α. Wells were then aspirated, washed, and further incubated with corresponding conjugated 
secondary antibody. Reaction was monitored upon addition of substrate solution, and absorbance read 
at 450nm. Values were extrapolated from a four parameter logistic curve, and represent mean ± SE, 
n=9 animals per group. Bars without a common superscript(w,x,y,z) are significantly different, p<0.05, 
as determined by ANOVA analyses with LSD and Tukey post hoc tests. AOM: azoxymethane, Zk-





Overall, all plasma samples had notably more sTNFR2 than sTNFR1 when compared on a weight 
basis (Figure 6-2). Little difference was observed for sTNFR1 among all animal groups with the 
exception of AOM injected Zk-Ob and control Zk-Ln animals which had lowest and highest levels 
respectively. AOM injected Zk-Ob rats had highest sTNFR2, followed by control Zk-Ob and SD 
groups. Soluble receptors may act as neutralizers or reservoirs for TNF-α, binding and releasing it 
into the plasma (Rojas-Cartagena et al. 2005). High TNF-α levels may therefore be attributed to 
increased sTNFR2, which could contribute to prolonged cytokine release in the plasma. TNFR2 is 
proposed to play a greater role in mediating cell survival signaling in comparison to TNFR1, possibly 
explaining the high sTNFR2 to sTNFR1 ratio in all groups (Higuchi and Aggarwal 1994b). 
Moreover, the AOM injected Zk-Ob group in particular shows lower and higher levels of sTNFR1 
and sTNFR2 respectively in comparison to control rats. Soluble receptors are also shed by tumors, 
and may play a role in their growth promotion. Studies have shown that measurement of soluble 
receptors, and not plasma TNF-α, is a better indicator of disease status (Gadducci et al. 1995). Further 
implications of TNFR in tumorigenesis are discussed in Study 2C. 
 
Plasma was also analyzed for o-tyrosine, n-tyrosine, and 8-OH-DGnc oxidative markers in 
collaboration with the Ottawa Health Research Institute (Ottawa, ON) (Figure 6-3). Relative amounts 
of ROS and RNS may be quantified by measuring respective reaction products such as tyrosine 
isomers via HPLC (Kumarathasan and Vincent 2003). Assessment of these gives further insight on 
physiological condition of the animal.  
 
Zk-Ob rats had significantly higher o-tyrosine and n-tyrosine levels in comparison to other groups. 
Little difference was seen in the 8-OH-DGnc marker with the exception of AOM injected Zk-Ln 
group, which had the lowest level. ROS and RNS are key links between obesity and cancer by 
generation of a pro-inflammatory environment. High levels of oxidative markers in Zk-Ob rats are 











Figure 6-2: Plasma levels of (A) sTNFR1 and (B) sTNFR2 in control and AOM injected Zk-Ob, 
Zk-Ln, and SD rats. 
Samples were incubated in a 96 well plate pre-coated with antibody to sTNFR1 or sTNFR2. Wells 
were then aspirated, washed, and further incubated with conjugated secondary antibody. Reaction was 
monitored upon addition of substrate solution, and absorbance read at 450nm. Values were 
extrapolated from a four parameter logistic curve, and represent mean ± SE, n=9 animals per group. 
Bars without a common superscript(x,y,z) are significantly different, p<0.05, as determined by ANOVA 
analyses with LSD and Tukey post hoc tests. AOM: azoxymethane, Zk-Ob: Zucker obese, Zk-Ln: 
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Figure 6-3: Plasma levels of (A) o-tyrosine, (B) n-tyrosine, and (C) 8-OH-DGnc in control and 
AOM injected Zk-Ob, Zk-Ln, and SD rats. 
Plasma ROS and RNS levels were measured by a highly sensitive HPLC assay (Kumarathasan and 
Vincent 2003). Values are mean ± SE, n=6 animals per group. Bars without a common superscript(x,y) 
are significantly different, p<0.05, as determined by ANOVA analyses with LSD and Tukey post hoc 
tests. Zk-Ob rats had highest levels of o-tyrosine and n-tyrosine in comparison to other groups. AOM: 
azoxymethane, Zk-Ob: Zucker obese, Zk-Ln: Zucker lean, SD: Sprague dawley, subscript c indicates 
control animals.  
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6.3 Results and Discussion, Study 2B: Assessment of tumor parameters in Zk-Ob, Zk-
Ln, and SD rats  
 
6.3.1 Methodological Approach  
Details of experimental procedures are provided in Chapter 4 Materials and Methods. Briefly, Zk-Ob, 
Zk-Ln, and SD rats were injected with AOM, and terminated after 30 weeks. Location and size of 
tumors and microadenomas along the colonic axis were recorded (Figure 6-4). Depending on their 
size, tumors were fixed in place with formalin, or excised and stored at -80°C or for further analyses. 




Figure 6-4: Presence of multiple colonic tumors in Zk-Ob rat. 
Following removal, colons were flushed with PBS and slit lengthwise. Tumors were identified for 
size and location, and excised or fixed in place for further analyses. Four tumors located in the distal 
region from a Zk-Ob rat colon are shown. Note variable size of tumors, and highly vascularized 
tumor tissue as depicted by the red coloring.  
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6.3.2 Tumor Parameters 
Characteristics of tumor numbers and size are described (Table 6-4). Zk-Ob animals had 100% tumor 
incidence, confirming these rats are indeed an excellent model for investigating the augmented risk of 
obesity associated colon cancer. Zk-Ln rats had a higher incidence compared to SD, indicating that 
this genotype is not resistant, and simply less sensitive than the obese counterparts towards 
carcinogenesis. Tumor burden and tumor multiplicity representing average number of tumors per 
tumor-bearing rat was also highest in Zk-Ob rats. SD rats had highest size per tumor bearing rat and 
group, although size of SD tumors was marginally different compared to Zk-Ob tumors. The number 
of microadenomas was also highest in Zk-Ob rats, followed by SD and Zk-Ln groups respectively. 
These findings also demonstrate that preneoplastic lesions grew at different rates, and whether this 
phenomena is due to the different biological make-up of the groups, or microenvironment, remains to 
be determined.   
 
Distribution of tumors along the colon is summarized in Table 6-5. Zk-Ob animals had greatest 
percentage of tumors along the most distal segment of the colon (0-4cm), while Zk-Ln and SD tumors 
were mostly located in the adjacent section (4-8cm). It was noted that tumors in the distal regions (0-
8cm) also had a larger size than those in proximal regions. The distribution pattern and size of tumors 
along the colonic axis in all groups demonstrated that colon tumorigenesis is different depending on 
the region of the colon. Phenotypical differences between distal and proximal colonic tumors are 














Table 6-4: Tumor Parameters of Zk-Ob, Zk-Ln and SD ratsa. 
 Zk-Ob Zk-Ln SD 
Total number of rats (AOM injected) 21 23 25 
Tumor incidence (%) 100 47.8 20.0 
Total number of tumors 78 15 5 
Tumor multiplicity a 
 
3.71 ± 1.92 1.36 ± 1.21 
 
1 ± 0 
 
Average tumor size (mm2)/tumor- 
bearing rat 
35 ± 0.17 
 
17 ± 0.13 
 
41 ± 0.28 
 
Average tumor size (mm2)/group  
 
38 ± 0.38 
 
22 ± 0.27 
 
41 ± 0.28 
 
Tumor Burden 1.31 ± 0.87 
 
0.3 ± 0.5 
 
0.41 ± 0.28 
 
Total Number of Microadenomas 7 0 3 
aColonic tumors were collected upon termination of Zk-Ob, Zk-Ln, and SD animals. Calculation 
details of tumor parameters are given in Chapter 4 Materials and Methods. Values expressed as 
means ± SD. Zk-Ob: Zucker obese, Zk-Ln: Zucker lean, SD: Sprague dawley. 
 
 
Table 6-5: Distribution and average size of tumors along the length of the colon in Zk-Ob, Zk-
Ln, and SD rats. 
Colon Segment (cm length)  
 A (0-4)a B (4-8) C (8-12) D (12-16) 
Zk-Obd 55.3b (30)c 34.0 (44) 8.5  (36) 2.1 (12) 
Zk-Ln 13.3 (12) 60.0 (29) 20   (23) 6.7 (1) 
SD 16.7 (16) 50.0 (45) 33.3 (29) 0   (1) 
aA-D represent 16cm of the unfixed colon, in 4cm sections starting from the rectal end, where A is the 
most distal segment, and D is most proximal. 
bPercentage of tumors present in the indicated colonic region. 
cValues in brackets represent average tumor sizes (mm2) in the corresponding colonic section.  
dZk-Ob: Zucker obese, Zk-Ln: Zucker lean, SD: Sprague dawley.  
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6.4 Results and Discussion, Study 2C: Assessment of protein expression patterns in 
tumors and colonic mucosa of Zk-Ob, Zk-Ln, and SD rats 
 
Elevated NF-κB levels have been implicated in disease progression of both cancer and obesity. 
Additionally, downstream signaling mediated by TNFR1 and TNFR2 is complex, and not yet fully 
explored. TNFR1 is generally recognized to contribute to death signals whereas TNFR2 favors a 
survival signal. Considerable evidence also exists for insulin resistance acting as a critical link 
between obesity and cancer progression. Insulin, IGF-IR, and IR transduce survival signals that 
promote carcinogenesis, and may act synergistically with TNF-α to provide a growth and survival 
advantage for developing tumors. Evaluation of these pathways via protein expression analyses gave 
further insight into possible interplays occurring in obesity associated colon cancer.   
6.4.1 Methodological Approach 
Details of experimental procedures are provided in Chapter 4 Materials and Methods. Protein 
analyses was carried out in tumors of Zk-Ob, Zk-Ln, and SD animals. For comparison purposes 
colonic mucosae were also analyzed in a similar manner from six different groups of animals: Zk-Ob, 
Zk-Ln and SD groups injected with AOM, and Zk-Obc, Zk-Lnc and SDc non-injected, control 
groups. Briefly, tumors and mucosae were homogenized and proteins separated by SDS-PAGE. 
Following transfer, membranes were incubated with primary, then AP conjugated secondary 
antibodies, and developed with BCIP/NBT solution. Specific proteins analyzed in tumors and colonic 
mucosae included TNF-α, TNFR1, TNFR2, NF-κB, IκBα, IKKβ, IRα, IRβ, IGF-IRα, and MAPK 
p42/p44. 
 
6.4.2 Protein Expression Patterns in Tumor Homogenates 
Tumor homogenates were analyzed for proteins expression of key players in TNF-α and NF-κB 
pathways including TNF-α, TNFR1, and TNFR2, NF-κB, IκBα, and IKKβ. In addition, modulators of 
the insulin and glucose homeostasis pathways, IGF-IRα, IRα, and IRβ were examined. Finally, tumor 






TNF-α, TNFR1, and TNFR2 protein expression 
TNF-α, TNFR1, and TNFR2 protein expression in tumors were determined by western blot (Figure 6-
5). Analyses of TNF-α and TNFR2 showed similar trends of Zk-Ob and SD tumors having higher 
expression than Zk-Ln. Two closely related bands were observed with TNFR1, and shared highest to 
lowest expression for Zk-Ob, SD, and Zk-Ln tumors respectively. Overall, there was higher protein 
expression for TNFR2 than TNFR1 in tumors from all groups.  
 
Roles of TNFR are diverse and are important for both cell death and survival outcomes. However, 
some studies have shown TNFR1 to be more critical for apoptotic signaling due to the presence of 
death domains (Fontaine et al. 2002). Previous studies in our lab have further demonstrated TNFR2 to 
be preferentially associated with cell survival (Raju and Bird, 2006). It is therefore important to note 
that Zk-Ob and SD tumors exhibited a phenotype favoring survival by expressing higher levels of 
TNFR2. These findings suggests that in presence of high TNF-α, tumors maybe upregulating or 
downregulating TNFR2 and TNFR1 expression respectively as a strategy to direct TNF-α as an 
instigator of cell survival. Plasma analyses further showed higher levels of sTNFR2 than sTNFR1, 
corroborating protein patterns found in tumors.  
 
Perhaps the physiological conditions and elevated TNF-α in Zk-Ob rats promoted increased levels of 
TNFR. Conversely, Zk-Ln tumors had lowest expression of TNFRs, indicating a decreased sensitivity 
of these lesions towards TNF-α.  
 
Soluble forms of TNFR1 and TNFR2 were further analyzed in tumor homogenates via ELISA, 
demonstrating higher levels of sTNFR2 overall (Appendix C). Zk-Ob tumors had more soluble 
receptor than SD, which further had higher levels than Zk-Ln tumors. It is quite possible that 
receptors were solubilized during preparation and lyses of cells, thus questioning the validity of this 










                    
                       
 
Figure 6-5: Representative western blots of TNF-α, TNFR1, and TNFR2 protein expression in 
tumors of Zk-Ob, Zk-Ln, and SD animals (A), and (B) Bar graphs of mean densitometric 
values.  
Tumor homogenates, 100 μg of protein per sample, were separated by SDS-PAGE, and transferred 
onto membranes. Following incubation with primary antibodies and corresponding AP-conjugated 
secondary antibodies, blots were developed with BCIP/NBT solution, and bands quantified by 
densitometric analyses. Values in (B) are pixels (arbitrary units) and are mean ± SE, n=6 per group. 
Each band represents a tumor from one animal, and groups are as indicated. Bars without a common 
superscript(x,y,z) are significantly different, p<0.05, as determined by ANOVA analyses with LSD and 
Tukey post hoc tests. Zk-Ob: Zucker obese, Zk-Ln: Zucker lean, SD: Sprague dawley.  
Zk-Ob Zk-Ln SD
TNF-α, 27/17 kDa 
TNFR1, 55 kDa 
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NF-κB, IκBα, and IKKβ protein expression 
NF-κB, IκBα, and IKKβ protein expression were determined by western blot (Figure 6-6). NF-κB and 
IκBα levels were significantly higher in Zk-Ob and SD tumors. An additional band was noted for 
IκBα, and showed no differences among the groups. IKKβ levels were highest in Zk-Ob tumors.  
 
Active p65 NF-κB levels showed significantly higher levels in Zk-Ob tumors in comparison to Zk-Ln 
and SD tumors (Figure 6-7). These results correlated with protein expression patterns shown by 
western blot for both NF-κB and IKKβ, the enzyme responsible for releasing NF-κB in its active 
form. NF-κB activity associated with high levels of IκBα was unexpected due to its role as an 
inhibitor of NF-κB. However, IκBα is transcribed by NF-κB, and higher levels in Zk-Ob and SD 
tumors may be a result of the increased NF-κB activity, trying to initiate a negative feedback signal. 





















Figure 6-6: Representative western blots of NF-κB, IκBα, and IKKβ protein expression in 
tumors of Zk-Ob, Zk-Ln and SD animals (A), and (B) Bar graphs of mean densitometric values.  
Tumor homogenates, 100 μg of protein per sample, were separated by SDS-PAGE, and transferred 
onto membranes. Following incubation with primary antibodies and corresponding AP-conjugated 
secondary antibodies, blots were developed with BCIP/NBT solution, and bands quantified by 
densitometric analyses. Values in (B) are pixels (arbitrary units) and are mean ± SE, n=6 per group. 
Each band represents a tumor from one animal, and groups are as indicated. Bars without a common 
superscript(x,y,z) are significantly different, p<0.05, as determined by ANOVA analyses with LSD and 
Tukey post hoc tests. Zk-Ob: Zucker obese, Zk-Ln: Zucker lean, SD: Sprague dawley.  
IKKβ, 87kDa  
NF-κB, 65kDa 
IκBα, 37 kDa 































































































Figure 6-7: Active p65 NF-κB levels in Zk-Ob, Zk-Ln, and SD tumors. 
Assay was carried out using the TransAM kit as per manufacturer instructions (Active Motif). 
Briefly, tumor homogenates, 10μg of protein per sample, were incubated with an oligonucleotide 
specific to NF-κB. Subsequent incubation with primary antibody specific to the p65 subunit was 
followed by exposure to HRP-conjugated secondary antibody and developing solution. Absorbance 
was read at 450nm. Values are mean ± SE, n=6 per group. Bars without a common superscript(x,y,z) 
are significantly different, p<0.05, as determined by ANOVA analyses with LSD and Tukey post hoc 































IGF-IRα, IRα, and IRβ protein expression 
IGF-IRα, IRα, and IRβ protein levels were determined via western blot (Figure 6-8). Expression for 
all these proteins was significantly higher in Zk-Ob and SD tumors in comparison to Zk-Ln. Both 
IGF-IR and IR are associated with tumor promotion, and are considered important factors in obesity 
associated tumorigenesis (Giovannucci 2001, Ma et al. 1999). High levels of these proteins in Zk-Ob 
tumors also corroborated with hyperinsulinemia and insulin resistance observed in these animals, 
which further contribute to an increased risk for cancer.  
 
MAPK p42/44 protein expression 
MAPK p42/44 protein levels were analyzed by western blot, and were observed to be notably higher 
in Zk-Ob tumors for both forms (Figure 6-9). MAPK, a serine/threonine kinase, can initiate, or be 
activated by a number of signaling pathways, including NF-κB (Pearson et al. 2001). This enzyme 
family is multi-functional, influencing cell differentiation, proliferation, and death. MAPK is also 
implicated in increasing NF-κB transcriptional activity (reviewed in Perkins and Gilmore 2006). It is 
apparent that Zk-Ob tumors had higher levels of MAPK p42/44 than Zk-Ln tumors. This may be 
related to the elevated levels of NF-κB, IR, and IGF-IRα signaling leading to the augmented growth 

















Figure 6-8: Representative western blots of IGF-IRα, IRα, and IRβ protein expression in 
tumors of Zk-Ob, Zk-Ln, and SD animals (A), and (B) Bar graphs of mean densitometric 
values.  
Tumor homogenates, 100 μg of protein per sample, were separated by SDS-PAGE, and transferred 
onto membranes. Following incubation with primary antibodies and corresponding AP-conjugated 
secondary antibodies, blots were developed with BCIP/NBT solution, and bands quantified by 
densitometric analyses. Values in (B) are pixels (arbitrary units) and are mean ± SE, n=6 per group. 
Each band represents a tumor from one animal, and groups are as indicated. Bars without a common 
superscript(x,y,z) are significantly different, p<0.05, as determined by ANOVA analyses with LSD and 
Tukey post hoc tests. Zk-Ob: Zucker obese, Zk-Ln: Zucker lean, SD: Sprague dawley.  
Zk-Ob Zk-Ln SD
IRβ, 95 kDa 
IRα, 125 kDa 

















































































                            
 
       
 
Figure 6-9: Representative western blot of MAPK p42/44 protein expression in tumors of Zk-
Ob, Zk-Ln, and SD animals (A), and (B) Bar graphs of mean densitometric values.  
Tumor homogenates, 100 μg of protein per sample, were separated by SDS-PAGE, and transferred 
onto membranes. Following incubation with primary antibodies and corresponding AP-conjugated 
secondary antibodies, blots were developed with BCIP/NBT solution, and bands quantified by 
densitometric analyses. Values in (B) are pixels (arbitrary units) and are mean ± SE, n=6 per group. 
Each band represents a tumor from one animal, and groups are as indicated. Bars without a common 
superscript(x,y,z) are significantly different, p<0.05, as determined by ANOVA analyses with LSD and 
Tukey post hoc tests. Zk-Ob: Zucker obese, Zk-Ln: Zucker lean, SD: Sprague dawley.  
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6.4.3 Protein Expression Patterns in Colonic Mucosae  
Colonic mucosal homogenates from control and AOM injected animals were analyzed for proteins 
expression of key players in TNF-α and NF-κB pathways including TNF-α, TNFR1, and TNFR2, 
NF-κB, IκBα, and IKKβ. In addition, modulators of the insulin and glucose homeostasis pathways, 
IGF-IRα, IRα, and IRβ were examined. Finally, mucosal samples were also analyzed for MAPK 
p42/44 enzyme. Overall, insignificant differences were seen between control and AOM injected 
colonic mucosal samples.  
 
TNF-α, TNFR1, and TNFR2 protein expression 
TNF-α, TNFR1, and TNFR2 protein expression were determined by western blot (Figure 6-10). 
Protein bands at 27 and 17 kDa were observed for TNF-α, possibly corresponding to the 
transmembrane and soluble protein forms respectively. Zk-Ob and SD rats had significantly higher 
levels of the 27kDa protein than Zk-Ln animals, with no difference between respective AOM and 
control groups. Overall, there was more 27kDa than 17kDa TNF-α for all groups. Higher levels of 
soluble 17 kDa TNF-α were observed in the control than AOM injected groups collectively. Within 
the AOM injected animals, Zk-Ln rats had lowest expression of 17kDa TNF-α 
 
Zk-Ob and SD rats had significantly higher levels of TNFR1 in comparison to Zk-Ln, while no 
difference was observed between AOM and control groups. Similarly, Zk-Ob and SD animals had 
higher TNFR2 expression in comparison to Zk-Ln, and no differences were seen between control and 












Figure 6-10: Representative western blots of TNF-α, TNFR1, and TNFR2 protein expression in 
colonic mucosae of (A) control and (B) AOM injected Zk-Ob, Zk-Ln, and SD animals, and (C) 
Bar graphs of mean densitometric values.  
Colonic mucosal homogenates, 300 μg of protein per sample, were separated by SDS-PAGE, and 
transferred onto membranes. Following incubation with primary antibodies and corresponding AP-
conjugated secondary antibodies, blots were developed with BCIP/NBT solution, and bands 
quantified by densitometric analyses. Values in (C) are pixels (arbitrary units) and are mean ± SE, 
n=6 per group. Each band represents a colon sample from one animal, and groups are as indicated. 
Bars without a common superscript(x,y,z) are significantly different, p<0.05, as determined by ANOVA 
analyses with LSD and Tukey post hoc tests. Zk-Ob: Zucker obese, Zk-Ln: Zucker lean, SD: Sprague 
dawley, subscript c indicates control animals.   
Zk-Ob Zk-Ln SD 
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TNFR2, 75 kDa 
B
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NF-κB, IκBα, and IKKβ protein expression 
NF-κB, IκBα, and IKKβ protein expression were determined by western blot (Figure 6-11). NF-κB 
and IKKβ levels are elevated in Zk-Ob and SD groups significantly more than Zk-Ln animals. In 
addition to the 87 kDa IKKβ band, another closely related band was visualized. IκBα levels were 
significantly lower in all AOM injected groups in comparison to their controls, while no differences 
were observed between the genotypes.  
 
Active NF-κB levels were significantly higher in Zk-Ob animals, and further increased in the 
corresponding AOM injected group in comparison to Zk-Ln and SD groups (Figure 6-12). No 
differences were found between Zk-Ln and SD control and AOM injected groups. High levels of 
active NF-κB in Zk-Ob rats corresponded to IKKβ protein levels as this enzyme is responsible for 





















Figure 6-11: Representative western blots of NF-κB, IκBα, and IKKβ protein expression in 
colonic mucosa of (A) control and (B) AOM injected Zk-Ob, Zk-Ln, and SD animals, and (C) 
Bar graphs of mean densitometric values.  
Colonic mucosal homogenates, 300 μg of protein per sample, were separated by SDS-PAGE, and 
transferred onto membranes. Following incubation with primary antibodies and corresponding AP-
conjugated secondary antibodies, blots were developed with BCIP/NBT solution, and bands 
quantified by densitometric analyses. Values in (C) are pixels (arbitrary units) and are mean ± SE, 
n=6 per group. Each band represents a colon sample from one animal, and groups are as indicated. 
Bars without a common superscript(x,y,z) are significantly different, p<0.05, as determined by ANOVA 
analyses with LSD and Tukey post hoc tests. Zk-Ob: Zucker obese, Zk-Ln: Zucker lean, SD: Sprague 
dawley, subscript c indicates control animals.   
Zk-Ob Zk-Ln SD
IKKβ, 87 kDa 
NF-κB, 65kDa 
IκBα, 37 kDa 
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Figure 6-12: Measurement of active p65 NF-κB levels in colonic mucosae of control and AOM 
injected Zk-Ob, Zk-Ln, and SD rats. 
Assay was carried out using the TransAM kit. Briefly, colonic mucosal homogenates, 10 μg of 
protein per sample, were incubated with an oligonucleotide specific to NF-κB. Subsequent incubation 
with primary antibody specific to the p65 subunit was followed by exposure to HRP-conjugated 
secondary antibody and developing solution. Absorbance was read at 450nm. Values are mean ± SE, 
n=6 per group. Bars without a common superscript(x,y,z) are significantly different, p<0.05, as 
determined by ANOVA analyses with LSD and Tukey post hoc tests. AOM: azoxymethane, Zk-Ob: 
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IGF-IRα, IRα, and IRβ protein expression 
IGF-IRα, IRα, and IRβ protein levels were determined via western blot (Figure 6-13). IGF-IRα levels 
were significantly increased in AOM injected Zk-Ob animals in comparison to SD, which were also 
higher than Zk-Ln rats. All three AOM injected groups had higher IGF-IRα than their respective 
controls. IRα expression was also significantly higher in Zk-Ob and SD animals than Zk-Ln. The only 
notable difference between control and AOM injected groups was present in Zk-Ob animals, which 
had the highest expression. Zk-Ob rats had highest levels of IRβ followed by SD and Zk-Ln groups 
respectively. The only difference present between AOM and control groups was in Zk-Ln animals, 
where AOM injected rats had higher expression of IRβ.   
 
MAPK p42/44 protein expression 
MAPK p42/44 protein levels were analyzed by western blot (Figure 6-14). AOM injected Zk-Ob and 
SD groups showed increased expression of both MAPK p42 and p44 in comparison to Zk-Ln rats, 
while no differences were seen among all control groups for both forms. Higher levels of p42 than 


















Figure 6-13: Representative western blots of IGF-IRα, IRα, and IRβ protein expression in 
colonic mucosae of (A) control and (B) AOM injected Zk-Ob, Zk-Ln, and SD animals, and (C) 
Bar graphs of mean densitometric values.  
Colonic mucosal homogenates, 300 μg of protein per sample, were separated by SDS-PAGE, and 
transferred onto membranes. Following incubation with primary antibodies and corresponding AP-
conjugated secondary antibodies, blots were developed with BCIP/NBT solution, and bands 
quantified by densitometric analyses. Values in (C) are pixels (arbitrary units) and are mean ± SE, 
n=6 per group. Each band represents a colon sample from one animal, and groups are as indicated. 
Bars without a common superscript(x,y,z) are significantly different, p<0.05, as determined by ANOVA 
analyses with LSD and Tukey post hoc tests. Zk-Ob: Zucker obese, Zk-Ln: Zucker lean, SD: Sprague 
dawley, subscript c indicates control animals.   
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Figure 6-14: Representative western blots of MAPK p42/44 protein expression in colonic 
mucosae of (A) control and (B) AOM injected Zk-Ob, Zk-Ln, and SD animals, and (C) Bar 
graphs of mean densitometric values.  
Colonic mucosal homogenates, 300 μg of protein per sample, were separated by SDS-PAGE, and 
transferred onto membranes. Following incubation with primary antibodies and corresponding AP-
conjugated secondary antibodies, blots were developed with BCIP/NBT solution, and bands 
quantified by densitometric analyses. Values in (C) are pixels (arbitrary units) and are mean ± SE, 
n=6 per group. Each band represents a colon sample from one animal, and groups are as indicated. 
Bars without a common superscript(x,y,z) are significantly different, p<0.05, as determined by ANOVA 
analyses with LSD and Tukey post hoc tests. Zk-Ob: Zucker obese, Zk-Ln: Zucker lean, SD: Sprague 
dawley, subscript c indicates control animals.   
MAPK p42/44
Zk-Obc Zk-Lnc SDcA 
MAPK p42/44
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Overall, the differences between control and AOM injected colon mucosae were not significant. Early 
stages of carcinogenesis exhibit more vulnerability towards transformations in the mucosa. Moreover, 
physiological conditions of the animal do not have global effects on cancer progression as some 
stages are more sensitive than others. Thus, the modest changes that are observed between control and 
AOM animals are possibly due to the mature stage of cancer in these animals. 
 
6.4.4 Comparison of protein expression between tumors and colonic mucosae  
 
Protein levels were compared between tumors and corresponding normal appearing colonic mucosae, 
presented on an equal protein basis (Figure 6-15). Similar patterns within tumors and mucosal groups 
were retained as described previously. Analyses indicated significantly higher protein levels in tumors 
from all groups than mucosae. It is interesting to note that Zk-Ob tumors in particular had relatively 
higher levels of TNFR2, NF-κB, IGF-IRα, and MAPK. These proteins are implicated in mediation of 
cell survival, and their increased presence in tumors substantiate their roles in providing a growth 
advantage. Overall, the remarkable distinction between tumor and mucosal protein levels 
demonstrated that changes in protein expression may be more specific to neoplastic lesions.  
   
Higher protein level of NF-κB is also substantiated by increased active NF-κB levels in tumors 









































































































































































































27 kDa 17 kDa
A 




               
Figure 6-15: Bar graphs of mean densitometric values showing comparisons between tumors 
and colonic mucosae in Zk-Ob, Zk-Ln, and SD rats for protein expression of (A) TNF-α, 
TNFR1, and TNFR2, (B) NF-κB, IκBα, and IKKβ, (C) IGF-IRα, IRα, and IRβ, and (D) MAPK 
p42/44. 
Densitometric values from tumor and colonic mucosae were compared to evaluate changes in protein 
expression. Three times protein was loaded for colon versus tumors samples. Thus, densitometry 
values from tumor data were adjusted to represent equal amounts of protein. Values are pixels 
(arbitrary units), and represent mean ± SE, n=6 per group. Bars without a common superscript(w,x,y,z) 
are significantly different, p<0.05, as determined by ANOVA analyses with LSD and Tukey post hoc 





























































































































Figure 6-16: Comparison between colonic mucosae and tumors in Zk-Ob, Zk-Ln, and SD rats 
for active NF-κB levels. 
Assay was carried out using the TransAM kit as per manufacture instructions. Briefly, colonic 
mucosal and tumor homogenates, 10 μg of protein per sample, were incubated with an 
oligonucleotide specific to NF-κB. Subsequent incubation with primary antibody specific to the p65 
subunit was followed by exposure to HRP-conjugated secondary antibody and developing solution. 
Absorbance was read at 450nm. Values are mean ± SE, n=6 per group. Bars without a common 
superscript(w,x,y,z) are significantly different, p<0.05, as determined by ANOVA analyses with LSD 
and Tukey post hoc tests. CM: colonic mucosae, T: tumors, Zk-Ob: Zucker obese, Zk-Ln: Zucker 
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6.4.5 IHC Analyses 
 
IHC analyses was performed on Zk-Ob, Zk-Ln, and SD tumor sections for NF-κB, IκBα, TNF-α, 
TNFR1, and TNFR2 proteins. Unlike immunoblotting which provided quantitative data, IHC was 
used to determine possible differences in the spatial expression of key molecules of interest. This 
methodology was used qualitatively and changes in protein levels in tumors were further compared 




One section from each tumor was stained with a combination of H&E stain. Hematoxylin stains the 
nuclei a blue-black color, while cytoplasm is stained pink by red counterstain eosin. Figure (6-17A) 
shows H&E sections of tumors with clusters of dysplastic crypts, infiltrating lymphocytes and stromal 
cells. Overall, a greater proportion of Zk-Ln and SD tumors were characterized as fibroadenomas. 
Figure (6-17B) shows normal appearing colonic crypts adjacent to tumor tissue.  
 
TNF-α 
IHC analyses for TNF-α showed overall diffuse staining throughout the tumor mass with no particular 
trend between the groups (Figure 6-18). Intense staining in the apical membrane was observed. It was 
important to note that luminal compartments of the tumor epithelium contained secretory products 
that exhibited intense staining. Three possibilities exist for the staining of luminal contents: 1) 
secretion of TNF-α by tumor tissue, 2) shedding of TNF-α bound to a membrane receptor, and 3) 








Figure 6-17: H&E staining of tumor sections from Zk-Ob, Zk-Ln, and SD animals showing (A) 
tumor (top panel 100x, bottom panel 200x), and (B) normal appearing tissue (400x). 
Tumors were sectioned and stained with H&E for observation of general morphology. (A) Marked 
dysplasia was seen in all tumor types. Note fibrous characteristics of SD tumor (black arrow). (B) 
Normal appearing colonic crypts were observed in each tissue type. Note the variability of crypt sizes 
in Zk-Ob colonic section as depicted by the different sizes of the crypt lumen (round arrow). 
Infiltrating lymphocytes in SD section were observed (red arrow). Zk-Ob: Zucker obese, Zk-Ln: 
Zucker lean, SD: Sprague dawley.  





         
 
Figure 6-18: IHC staining for TNF-α in Zk-Ob, Zk-Ln, and SD tumor sections (400x). 
Sections were deparaffinized and dehydrated, incubated in blocking buffer, primary, and biotinylated 
secondary antibody respectively. Reaction was monitored following addition of enzyme conjugate 
and DAB chromagen, and sections were counterstained, rehydrated, and mounted with coverslips. 
Note marked staining in secretory materials exhibiting particular reactivity to antibody (black 
arrows), and intense staining of apical membrane (red arrow). Zk-Ob: Zucker obese, Zk-Ln: Zucker 






TNFR1 and TNFR2 
 
Localized intense staining for TNFR1 in epithelial cells and apical membrane was observed in all 
tumors (Figures 6-19). Secretory products with intense staining in the lumen of crypts were noted, 
possibly corresponding to soluble forms of receptors. Unexpectedly, diffuse nuclear staining was also 
seen throughout the tumor mass. 
 
As in TNFR1, a similar staining pattern was observed for TNFR2 (Figure 6-20). Intense staining in 
the membrane and secretory products were observed, more notably than TNFR1. A similar pattern 
was seen with western blot analyses, where expression of TNFR2 was significantly higher that 
TNFR1 in tumors. Nuclear staining was more prominent in comparison to TNFR1. Zk-Ln tumors 
exhibited more diffuse staining in comparison to other groups.  
 
NF-κB and IκBα 
Both localized as well as diffuse staining was observed for p65 NF-κB, particularly in the apical 
membranes (Figure 6-21). Nuclear staining was more abundant in Zk-Ob tumors than Zk-Ln and SD, 
corresponding to high levels of active NF-κB determined previously. Zk-Ln and SD tumors had a 
higher proportion of stromal cell populations compared to Zk-Ob, which also exhibited marked 
reactivity to the antibody. No discernable pattern was observed between tumor groups for IκBα. 
Diffuse staining throughout the tumor mass with occasional nuclear staining was present (Figure 6-
22) 
 
In general, ICH analyses demonstrated localized intense staining in stromal elements of the tissue. It 
can therefore be speculated that there is communication present between the tumor and its 
microenvironment, which facilitates growth progression. For example, TNF-α present in the stroma 
can affect structure remodeling via inducing MMP, promote angiogenesis, and recruit macrophages 










         
 
Figure 6-19: IHC staining for TNFR1 in Zk-Ob, Zk-Ln, and SD tumor sections (400x). 
Sections were deparaffinized and dehydrated, incubated in blocking buffer, primary, and biotinylated 
secondary antibody respectively. Reaction was monitored following addition of enzyme conjugate 
and DAB chromagen, and sections were counterstained, rehydrated, and mounted with coverslips. 
Note marked staining in secretory materials exhibiting particular reactivity to antibody in Zk-Ob 
tumor (red arrow), and intense staining of apical membrane in Zk-Ln and SD tumors (black arrow). 









       
 
 
Figure 6-20: IHC staining for TNFR2 in Zk-Ob, Zk-Ln, and SD tumor sections (400x). 
Sections were deparaffinized and dehydrated, incubated in blocking buffer, primary, and biotinylated 
secondary antibody respectively. Reaction was monitored following addition of enzyme conjugate 
and DAB chromagen, and sections were counterstained, rehydrated, and mounted with coverslips. 
Note marked staining in secretory materials exhibiting particular reactivity to antibody (black 
arrows), and an area of intense nuclear staining in Zk-Ob tumor (red arrow). Note: a dividing cell 








        
 
Figure 6-21: IHC staining for NF-κB in Zk-Ob, Zk-Ln, and SD tumor sections (400x). 
Sections were deparaffinized and dehydrated, incubated in blocking buffer, primary, and biotinylated 
secondary antibody respectively. Reaction was monitored following addition of enzyme conjugate 
and DAB chromagen, and sections were counterstained, rehydrated, and mounted with coverslips. 
Note marked staining in apical membranes (black arrows), and nuclear staining in Zk-Ob tumors 
(round arrow). Fibroblasts in Zk-Ln tumors also exhibited particular reactivity to antibody (red 









        
 
 
Figure 6-22: IHC staining for IκBα in Zk-Ob, Zk-Ln, and SD tumor sections (400x). 
Sections were deparaffinized and dehydrated, incubated in blocking buffer, primary, and biotinylated 
secondary antibody respectively. Reaction was monitored following addition of enzyme conjugate 
and DAB chromagen, and sections were counterstained, rehydrated, and mounted with coverslips. 
Note nuclear staining present in all groups (black arrows). Zk-Ob: Zucker obese, Zk-Ln: Zucker lean, 








Study 3: Differences in protein expression patterns in distal and proximal 
tumors of Zk-Ob rats. 
7.1 Study Background and Objectives 
In study 2B, it was observed that the tumor distribution pattern along the colonic axis was different in 
Zk-Ob versus Zk-Ln rats (Table 6-5). To be specific, it was noted that the majority of tumors in Zk-
Ob rats were located in most distal region of the colon. This observation was in keeping with recent 
interests generated in the field of cancer biology that proximal and distal tumors represent 
biologically different disease states. An overall abundance of tumors in Zk-Ob rats allowed a more 
detailed comparison of tumor phenotype with regards to location along the colonic axis. 
 
Evidence from the last decade has established that colon carcinogenesis originating from different 
colonic regions, distal and proximal, represent two individual disease states. Incidence rates of distal 
versus proximal tumors also differ, and are affected by geographical status, age, gender, shifting 
dietary patterns, and physical inactivity (Iacopetta 2002, Distler and Holt 1997).  
 
Distal and proximal colons are distinct organs representing different developmental, anatomical, and 
functional properties (Gervaz et al. 2004). In the same respect, cancers appearing in these two sites 
have individual properties. Tumors along the colonic axis have different embryonic origins and 
unique biological and genetic properties (Lindbolm 2001). Previous studies in our lab have 
demonstrated inconsistencies along the colonic axis during experimental colon carcinogenesis as ACF 
appeared earlier and more rapidly in the distal versus proximal colon (Bird 1995). 
 
Mechanisms by which these lesions develop, and their growth response to genetic and environmental 
variables also differ (Iacopetta 2002). Distal tumors follow the polyp-carcinoma sequence as 
proposed in the Vogelstein model, and are characterized by chromosomal instability. More steady 
proximal tumors develop via inherited nonpolyposis colon cancer, and share microsatellite instability 
(Bufill 1990). Evaluation of the differing phenotypes of distal and proximal tumors will give further 
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insight into directing future epidemiological studies, as well as diagnostic and treatment approaches 
for colon cancer. 
 
Importantly, the association between obesity and colon cancer is more often seen with the distal 
rather than proximal colon (Gunter and Leitzmann 2006). However, the cellular and mechanistic 
changes involved are yet to be elucidated. Due to the high incidence of tumors in Zk-Ob animals in 
this study, it was possible to investigate differences in distal versus proximal lesions with regards to 
obesity associated colon cancer.  
 
Specific objective of this study was:  
To determine if tumors in Zk-Ob rats present in the distal colon exhibit different phenotypes 
from those present in the proximal colon. In particular, expression of key proteins of the 
TNF-α, NF-κB and insulin pathways were investigated as identified below:  
• TNF-α, TNFR1, and TNFR2 
• NF-κB, IκBα, and IKKβ 
• IRα, IRβ, and IGF-IRα 
• MAPK p42/p44 
  
7.2 Methodological Approach 
Details of experimental procedures are provided in Chapter 4 Materials and Methods. Briefly, Zk-Ob, 
rats were injected with AOM, and terminated after 30 weeks. Location and size of tumors along the 
colonic axis were recorded. Tumors were excised and stored at -80°C for further analyses. Zk-Ob 
tumors originating from distal colon (0-4cm from the rectal end) or proximal colon (8-16 cm from the 
rectal end) were selected, homogenized and proteins were separated by SDS-PAGE. Following 
transfer, membranes were incubated with primary, then AP conjugated secondary antibodies, and 
developed with BCIP/NBT solution. Specific proteins analyzed in tumors included TNF-α, TNFR1, 




7.3 Results and Discussion 
Study 2B demonstrated a higher tumor distribution and size in the distal versus proximal colon, 
leading to further investigation into possible differences in tumor phenotype. Due to high tumor 
incidence in Zk-Ob animals, it was possible to analyze tumors from the distal and proximal regions 
(0-8cm and 8-16cm from the rectal end respectively) for possible differences in protein expression in 
TNF-α, NF-κB and insulin pathways.  
 
While no difference was seen in the levels of both 17 and 27kDa TNF-α, levels of TNFR1 and 
TNFR2 were lower and higher respectively in distal tumors (Figure 7-1). NF-κB and IKKβ 
expression were significantly higher in distal tumors, while IκBα levels were higher in proximal 
tumors (Figure 7-2). Compared to the levels noted in the proximal tumors, all of IGF-IRα, IRα, and 
IRβ levels were significantly higher in distal tumors (Figure 7-3). With regards to MAPK, p42 
subunit had similar expression among tumors regardless of their location, while p44 level was higher 
in distal tumors (Figure 7-4). 
 
In general, higher expression was observed in distal rather than proximal tumors for all proteins that 
were evaluated. Upregulation of NF-κB pathway may correlate with increased cell survival and 
growth, promoting increased tumorigenesis in the distal colonic axis. Higher levels of TNFR2 versus 
TNFR1 once again suggest the tumor phenotype to be directed towards the survival outcome of TNF-
α pathway. The increased sizes of distal tumors further correspond to upregulation of survival 
signaling, supporting the prominent association between obesity and colon cancer in the distal rather 
than proximal colon. Results from this study support the observation that distal and proximal 












                     
 
 
Figure 7-1: Representative western blots of TNF-α, TNFR1, and TNFR2 protein expression in 
distal and proximal tumors of Zk-Ob rats (A), and (B) Bar graphs of mean densitometric 
values.  
Tumors were selected from distal (0-8cm) and proximal (8-16cm) regions of the colon, measured 
from the rectal end. Tumor homogenates, 100 μg of protein per sample, were prepared for western 
blot analyses, separated by SDS-PAGE, and transferred onto membranes. Following incubation with 
primary antibodies and corresponding AP-conjugated secondary antibodies, blots were developed 
with BCIP/NBT solution, and bands quantified by densitometry analyses. Values in (B) are pixels 
(arbitrary units) representing mean ± SE, n=6 per group. Each band represents a tumor from one 
animal, and groups are as indicated. Bars without a common superscript(x,y) are significantly different, 
p<0.05, as determined by t-test. Zk-Ob: Zucker obese, Zk-Ln: Zucker lean, SD: Sprague dawley.  
ProximalDistal
TNF-α, 27/17 kDa 
TNFR1, 55 kDa 






















































































Figure 7-2: Representative western blots of NF-κB, IκBα, and IKKβ protein expression in distal 
and proximal tumors of Zk-Ob rats (A), with (B) Bar graphs of mean densitometric values.  
Tumors were selected from distal (0-8cm) and proximal (8-16cm) regions of the colon, measured 
from the rectal end. Tumor homogenates, 100 μg of protein per sample, were separated by SDS-
PAGE, and transferred onto membranes. Following incubation with primary antibodies and 
corresponding AP-conjugated secondary antibodies, blots were developed with BCIP/NBT solution, 
and bands quantified by densitometry analyses. Values in (B) are pixels (arbitrary units) representing 
mean ± SE, n=6 per group. Each band represents a tumor from one animal, and groups are as 
indicated. Bars without a common superscript(x,y) are significantly different, p<0.05, as determined by 
t-test. Zk-Ob: Zucker obese, Zk-Ln: Zucker lean, SD: Sprague dawley. 
ProximalDistal
























































































Figure 7-3: Representative western blots of IGF-IRα, IRα, and IRβ protein expression in distal 
and proximal tumors of Zk-Ob rats (A), with (B) Bar graphs of mean densitometric values.  
Tumors were selected from distal (0-8cm) and proximal (8-16cm) regions of the colon, measured 
from the rectal end. Tumor homogenates, 100 μg of protein per sample, were prepared for western 
blot analyses, separated by SDS-PAGE, and transferred onto membranes. Following incubation with 
primary antibodies and corresponding AP-conjugated secondary antibodies, blots were developed 
with BCIP/NBT solution, and bands quantified by densitometry analyses. Values in (B) are pixels 
(arbitrary units) representing mean ± SE, n=6 per group. Each band represents a tumor from one 
animal, and groups are as indicated. Bars without a common superscript(x,y) are significantly different, 
















































































                       
 
                           
 
Figure 7-4: Representative western blot of MAPK p42/44 protein expression in distal and 
proximal tumors of Zk-Ob rats (A), with (B) Bar graphs of mean densitometric values.  
Tumors were selected from distal (0-8cm) and proximal (8-16cm) regions of the colon, measured 
from the rectal end. Tumor homogenates, 100 μg of protein per sample, were separated by SDS-
PAGE, and transferred onto membranes. Following incubation with primary antibodies and 
corresponding AP-conjugated secondary antibodies, blots were developed with BCIP/NBT solution, 
and bands quantified by densitometry analyses. Values in (B) are pixels (arbitrary units) representing 
mean ± SE, n=6 per group. Each band represents a tumor from one animal, and groups are as 
indicated. Bars without a common superscript(x,y) are significantly different, p<0.05, as determined by 



































General Discussion and Conclusion 
The primary objective of this thesis was to investigate changes in tumor phenotype as affected by an 
obese physiological state. In particular, it was postulated that physiologically elevated TNF-α in an 
obese state will induce increased expression of transcriptionally active NF-κB in tumors, which 
subsequently transcribes genes crucial to cell survival. Insulin resistance, oxidative stress, and a pro-
inflammatory environment are few of the biological consequences of elevated TNF-α and NF-κB 
pathway activation, and further contribute to disease progression. It was thereby hypothesized that 
tumors in obesity associated colon cancer will have accelerated growth due to their resistance towards 
TNF-α mediated cytotoxicity, and their ability to use TNF-α mediated responses in favor for growth. 
Three major studies were conducted to investigate this hypothesis, and a brief discussion of major 
findings follows.  
 
In Study 1, HT-29 colon adenocarcinoma cells were used as a preliminary model to investigate 
cellular and molecular changes associated with the TNF-α resistant phenotype. The main finding 
demonstrated the ability of HT-29 cells to resist TNF-α induced cytotoxicity is due to augmented 
expression of NF-κB. Elevated levels of NF-κB in response to exogenous TNF-α supported that 
hypothesis that the NF-κB pathway is critical for cell survival. Inhibition of NF-κB via SJW treatment 
demonstrated that HT-29 cells could be sensitized towards TNF-α mediated cytotoxicity, further 
substantiating the role of NF-κB in TNF-α resistance. Upregulation of TNFR2, and decreased 
expression of TNFR1 upon TNF-α treatment suggests another strategy by which cells are utilizing 
exogenous TNF-α for survival. This study provided important clues as to what may be expected for 
investigating the TNF-α resistant phenotype in tumors, and supported the working hypothesis that 
chronic exposure to elevated TNF-α will exert a tumor promoting effect.  
 
In study 2, Zk-Ob rats were used as a model to investigate tumor phenotype in obesity associated 
colon cancer due to their inherent elevated TNF-α levels and metabolic dysregulation. Lean 
counterparts Zk-Ln rats, and SD rats functioned as control groups. It was hypothesized that elevated 
levels of TNF-α in Zk-Ob animals would exert a tumor promoting effect by inducing increased 




The physiological differences among the three animal genotypes were remarkable. As expected, the 
body weights of Zk-Ob rats were significantly higher than Zk-Ln and SD groups. It was noted that 
AOM injected tumors bearing animals had lower body weights than non-injected animals. This could 
be due to compromised food intake related to physiological distress from tumorigenesis. Zk-Ln rats, 
while having significantly lower body weights than the SD rats, had a higher tumor incidence. This 
suggests that a lean body mass is not necessarily protective to carcinogenesis, and emphasizes 
genotype to be crucial in determining the tumor outcome. It was also noted that organ weights, 
particularly liver and kidney weights of the Zk-Ob rats, were heavier than Zk-Ln and SD groups. 
Previous studies have indicated Zk-Ob rats to be sensitive to liver steatosis and kidney disease (Raju 
and Bird 2006).  
 
AOM injected Zk-Ob rats had a notably higher spleen weight than rest of the groups, suggesting that 
the immune system in Zk-Ob rats was highly sensitive to the presence of tumors. These animals 
exhibit a chronic inflammatory state and how immune cells may be participating in tumorigenesis 
remains to be evaluated.  
 
Hematological assessment of tumor bearing rats showed a few key differences. In particular, 
monocyte and platelet counts were significantly elevated in Zk-Ob rats than Zk-Ln or SD groups. 
Both of these blood components affect carcinogenesis. Monocytosis occurs in response to chronic 
inflammation, physiological stress, and cancer. Upon entering tissues, monocytes become 
macrophages, which are known generators of TNF-α. Tumor associated macrophages particularly 
have critical roles in tumor growth promotion which are still under review (Hussein 2006). In 
addition, platelets are involved in metastasis of cancer cells, and serve as a source for cytokines, 
growth factors, and bioactive lipids (Mousa 2006). Whether these two blood components are playing 
any roles in obesity associated colon carcinogenesis remains to be determined.  
 
Plasma values for insulin, leptin, and TNF-α corroborated previous observations that Zk-Ob rats have 
elevated levels of these hormones and cytokine than Zk-Ln and SD counterparts (Zucker and Zucker 




Evaluation of oxidative markers demonstrated notably higher levels in Zk-Ob animals than Zk-Ln and 
SD rats. It was noted that o-tyrosine and n-tyrosine were abundant in Zk-Ob regardless of the 
presence of tumors. This clearly supports previously published research that Zk-Ob rats are in a 
constant state of inflammation and have increased levels of ROS (Vincent et al. 1999). It is important 
to note that the pro-inflammatory state in Zk-Ob rats due to high levels of ROS and TNF-α may be 
conducive to generation of pre-neoplastic lesions that have potential to develop into tumors, whereas 
Zk-Ln or SD rats do not exhibit this state to the same degree.  
The role of inflammation in a number of chronic illnesses including cancer is an important area under 
active investigation (Macarthur et al. 2004). Whether chronic inflammation supports tumor growth or 
is co-carcinogenic in nature remains to be established. Previous studies suggest that the inflamed 
colon is highly sensitive to colon carcinogenesis, while sustained inflammation may not necessarily 
promote the growth of pre-existing preneoplastic lesions (Baijal et al. 1998). Inflammation is a 
complex process that may differ depending on the type of inflammatory agent, duration, and severity 
of the inflammation, as well as the physiological state of the host organism. Whereas there is 
agreement that inflammation plays a key role in cancer, specific effects during initiation and 
promotional stages of carcinogenesis remains to evaluated.  
Tumor outcome and incidence data revealed important information. As expected, tumor incidence 
and multiplicity were higher in Zk-Ob rats than Zk-Ln. It was interesting to note however, that Zk-Ln 
rats had a higher tumor incidence and multiplicity than SD, suggesting that genotype and 
physiological status of the host is important to tumor development. Most studies on experimentally 
induced colon carcinogenesis have used male SD rats, while this study used female rats. The role of 
estrogens in cancer is not yet fully understood, and hormonal profiles of these animals may have had 
additional effects. Furthermore, it is convention to use a dosage of 15mg/kg body weight AOM 
carcinogen to induce carcinogenesis. Due to the known increased sensitivity of Zk-Ob rats to 
carcinogenesis, a 10mg/kg body weight dose was given in this study to avoid over-toxicity to the 
animals. This lower dosage of carcinogen may also explain the lower tumor incidence in SD rats, 
which are less sensitive to cancer than the Zucker strain.  
While tumor incidence was higher in Zk-Ln than SD rats, SD tumors were larger in size. It can 
therefore be suggested that exogenous factors such as TNF-α may be more important in augmenting 
survival and progression of selected lesions. Moreover, an increased level of TNF-α before initiation 
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of carcinogenesis may be more crucial for enhanced tumor incidence and tumor multiplicity than 
afterwards.  
In this study, tumors were markedly distinct from colonic mucosa by increased protein expression. It 
was noted that all tumors, regardless of their origin exhibited elevated levels of TNF-α, TNFR, NF-
κB, IKKβ, IR, IGF-IR, and MAPK, supporting the concept that these proteins are important for their 
growth. Zk-Ob and SD tumors shared similar patterns of protein levels, although Zk-Ob animals had 
a higher number of tumors, while SD tumors were larger in size. These observations indicate that 
tumor populations among the groups exhibited heterogeneity that may have been influenced by the 
genotype and physiological conditions of the animals (Figure 8-1). In particular, physiological 
circumstances in the Zk-Ob animals may favor preneoplastic lesions to tumor development by 
upregulating survival pathways. In SD rats, fewer of these lesions progressed into tumors. Zk-Ln 
tumors on the other hand, were least responsive to growth. It was clear that tumors in Zk-Ob rats 
exhibited a more aggressive phenotype than those in the Zk-Ln and SD rats. This observation 
provides support to the contention that tumor microenvironment plays an important role in providing 
















Figure 8-1: Hypothetical scheme to describe biological heterogeneity of tumorigenesis as 
affected by physiological conditions.  
Growth potential of tumors is affected by genotype and physiological status of the host. Factors such 
as TNF-α, inflammation and insulin resistance may cooperatively contribute to tumorigenesis. Lesion 
A adapts rapidly to external growth factors, but is smaller in size than lesion B, which is well 
equipped for autonomous growth. Finally, lesion C has slow adaptation and growth. Zk-Ob tumors 
primarily resembled phenotype A, with some B and C lesions as well. SD rats had tumors 
predominantly with phenotype B, as demonstrated by their large size, and some C phenotypical 
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Biochemical analyses of tumor tissues and colonic mucosae supported the concept that augmented 
expression of molecules associated with growth and survival is common to tumor tissue. NF-κB as 
well as specific receptors such as TNFR2, IR, and IGF-IR appear to be central to tumor phenotype. 
Role of these molecules in carcinogenesis has been extensively reviewed (Gunter and Leitzmann 
2006, Lin and Karin 2003). It is well known that many of these molecules are involved in signaling 
pathways eventually influencing and co-operating with each other in rendering growth autonomy to 
the tumor tissue. Overall, Zk-Ob tumors exhibited highest levels of proteins that Zk-Ln and SD 
groups, supporting that physiological status of these animals had a notable impact on tumor 
phenotype with regards to protein expression. A schematic representation of pathway interactions and 
their effect on tumor promotion is given in Figure 8-2.  It is important to note that this representation 
is not inclusive, and is an attempt to explain possible circumstances that promote tumorigenesis. 
Further study into these associations and pathway cross talk is warranted.  
It is important to note that minor differences in physiological and biochemical parameters were found 
between respective AOM injected and control animals from the three genotypes. This observation 
suggests that most notable changes due to carcinogen injections occur in early stages of cancer. In 
addition, Zk-Ob and SD rats had very similar levels of plasma and protein parameters. This maybe 
due to the heavier body weight and higher plasma TNF-α in SD rats, contributing to a physiological 
similarity to Zk-Ob rats. Although, caution must be exercised in interpretation of results, as tumor 
















Figure 8-2: Multiple pathway interactions promoting tumorigenesis. 
Elevated levels of TNF-α promote NF-κB activity, inflammation, and insulin resistance, while these 
factors can also upregulate TNF-α levels. Insulin resistance, inflammation and associated ROS and 
RNS may also initiate NF-κB, and vice versa. TNFR2 appears to be upregulated in the presence of 
exogenous TNF-α in comparison to TNFR1. The interplay of these mechanisms appears to provide a 





















The hypothesis of this research was that Zk-Ob tumors will exhibit a phenotype that would exhibit 
resistance to TNF-α. To elaborate, it was speculated that elevated levels of exogenous TNF-α may 
provide additional stimulus to developing preneoplastic lesions, which in turn would adjust their 
biological make up to upregulate signals leading to survival and growth. For example, in this study it 
was observed that pathway activity of NF-κB was elevated in Zk-Ob tumors. Also, TNFR2, which is 
implicated in mediation of survival outcomes, was upregulated in comparison to TNFR1.   
 
Whereas this hypothesis is congruent to ongoing interest in TNF-α, it was recognized that Zk-Ob rats 
had elevated levels of a number of additional active components implicated in carcinogenesis. 
Physiological levels of insulin and IGF-IR are elevated along with TNF-α in Zk-Ob, whereas these 
are relatively lower Zk-Ln and SD rats. Previously it has been shown that insulin and IGF-IR are 
important growth factors for gastrointestinal tissue and provide protection to several cell types, 
including colon cancer cells, against pro-apoptotic signals (Remacle-Bonnet et al. 2000). The 
presence of elevated insulin, IGF-IR and TNF-α could act synergistically to provide superior survival 
and growth conditions to developing preneoplastic lesions and tumors. It has been demonstrated in 
cancer cell lines that activated NF-κB is also involved in IGF mediated cell survival. Moreover, 
inhibition of NF-κB and MAPK is crucial for reversing the survival signal mediated via IGF, as well 
as TNF-α (Remacle-Bonnet et al. 2000). Substantial evidence exists suggesting that TNF-α, IGF, and 
insulin signaling cross talk, and work synergistically to provide an ideal growth environment for 
tumors developing in the colon.  
 
Therefore, while it is reasonable to suggest that while TNF-α and associated signaling is playing a 
major role, participation of other molecules cannot be ruled out. Moreover, biological heterogeneity 
among preneoplastic lesions and the fact they may respond differently to physiological modulators 
depending on their biological make up, developmental stage, and location of the colons must be 
considered.  
Presence of elevated IGF-IR and IR in Zk-Ob tumors raises an interesting question, as the small 
intestine and colon do not require receptor mediation for glucose uptake. Thus, the role of insulin and 
more importantly, related receptors in colonic tumors becomes an important consideration. Other 
studies have demonstrated insulin associated tumor growth promotion (Giovannucci 2001). Possible 
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mechanisms involve activation of NF-κB and survival signaling, although further study in this area is 
required. 
The location of tumors along the colonic axis in Zk-Ob versus Zk-Ln or SD rats was also different, 
supporting the emerging concept that genotype/physiological state of the host affects development 
and distribution of tumors. High number of tumors in Zk-Ob rats allowed investigation into whether 
distal colonic tumors are different from those from proximal regions in the same host in Study 3. 
By examining expression levels of various proteins as favoring tumor growth, it may be concluded 
that distal tumors exhibit a superior phenotype than proximal tumors. To be specific, increased levels 
of TNFR2, NF-κB, IGR-IRα, and IR were observed in distal tumors. It is possible that developing 
tumors have variable access to systemic modulators depending on their location in the colon. Little 
information is known on the vascular supply of distal versus proximal lesions, and further study 
would give insight into growth characteristics of tumors in different regions of the colon. As stated 
previously, the colon consists of different compartments differing from each other anatomically, 
developmentally, and physiologically. It is thereby reasonable to assume that preneoplastic lesions 
occurring in different regions would also behave and respond differently.  
The distal colon responds quite actively to inflammation, and an increase in inflammatory cells and 
their aggregates are more commonly observed in the distal rather than proximal colon (personal 
communication, RB). In addition, the distal colon responds differently to AOM, and the appearance 
and growth of preneoplastic ACF differ according to colonic regions. Most immune activity in the 
colon is attributed to gut associated lymphoid tissue (GALT). Previous studies have shown that in 
carcinogen injected mice, a significant correlation between tumors and GALT tissue was observed in 
the distal rather than proximal colon (Carter et al. 1994). Interestingly, there was no such relationship 
between ACF and GALT, indicating differing responses of preneoplastic and neoplastic lesions. It is 
also possible that as selected preneoplastic lesions develop into tumors, GALT may develop in 
response to presence of tumors.  
Epidemiologically, proximal tumors appear more prominently in the elderly, possibly due to slower 
growth rates (Iacopetta 2002). In North American populations, the incidence of proximal tumors is at 
a rise, making it important to study biological differences among distal and proximal tumors, and the 
factors affecting their incidence. The preliminary findings in this study are noteworthy, and support 
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the conjecture that distal and proximal colons are two different organs, and tumorigenesis in these 
two sites also represent two different disease states. 
 
Conclusions  
Research documented in this thesis demonstrated that the physiological status of the host intricately 
affects tumor phenotype. In particular, the TNF-α resistant phenotype is involved with multiple 
signaling interplays as demonstrated by both in vitro and animal models.  
HT-29 cells treated with exogenous TNF-α exhibited elevated levels of NF-κB, suggesting that this 
pathway is critical for cell survival signaling. A similar response was seen in vivo with the Zk-Ob 
animal model.  
Zk-Ob rats exhibited a number of differences with regards to physiological parameters from their Zk-
Ln or SD counterparts. Some of these differences were not expected, and included increased plasma 
level of oxidative stress markers, and increased number of platelets and monocytes in Zk-Ob than Zk-
Ln or SD rats. Distribution pattern of colonic tumors in Zk-Ob rats showed a higher number in distal 
than in proximal regions compared to Zk-Ln and SD rats. 
Protein expression levels differentiated neoplastic tissue from the normal appearing colonic mucosae. 
In particular, all tumors expressed reduced TNFR1 and increased levels of TNFR2, NF-κB, IKKβ, IR, 
IGF-IR, and MAPK compared to their surrounding normal appearing mucosae.  
Tumors appearing in Zk-Ob rats exhibited significantly higher levels of the proteins involved in 
augmented activity of NF-κB, supporting the hypothesis elevated levels of TNF-α is tumor 
promoting. Moreover, insulin and IGF-IR may exert a synergistic effect with TNF-α to provide 
growth advantage to tumors.  
The level of specific proteins such as TNFR1, TNFR2, NF-κB, IR, IGF-IR, and MAPK p44 were 
differently expressed in distal than proximal colonic tumors in Zk-Ob rats. This observation 
suggested that development of tumors in different regions of the colon differ under the same 
physiological conditions.  
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For future studies, it would be important to evaluate gene and protein products of NF-κB transcription 
related to cell survival to further elucidate its role in tumor promotion. Moreover, it would be 
important to look at microscopic preneoplastic lesions to determine whether these phenotypes are 
present at early stages of carcinogenesis. This would also give insight into the cross talk between NF-
κB activation, inflammation and insulin resistance and how these mechanisms interplay to provide a 
favorable environment for tumorigenesis. Furthermore, it is necessary to assess the response of 
obesity-associated tumors to known chemotherapeutics. Effects of drugs may be different in altered 








  Abbreviations 
ACF    aberrant crypt foci 
ALT    alanine aminotransferase  
ANOVA   analysis of variance 
AP    alkaline phosphatase 
APC    adenomatous polyposis coli 
AO    acridine orange  
AOM    azoxymethane 
AST    aspartate aminotransferase  
BCIP/NBT                                  5-Bromo-4-Chloro-Indolyl-Phosphatase/ Nitroblue tetrazolium 
CB    conjugated bilirubin 
CBC    complete blood count 
CK    creatinine kinase 
DAB    3,3-diaminobenzidine tetrahydrochloride 
DAG    1,2-diacylglyercol 
DD    death domain 
DMH    1,2-dimethylhydrazine  
EGCG    epigallocatechin gallate 
ELISA    enzyme linked immunosorbent assay 
EMSA    electrophoretic mobility shift assay 
EtBr    ethidium bromide 
FADD    Fas associated death domain 
FasL    Fas ligand    
FLIPL    FLICE inhibitory protein 
GALT    Gut -associated lymphoid tissue 
HAQ    1-hydroxyanthraquinone  
Hb      hemoglobin  
HCT     hematocrit   
HDL    high density lipoprotein 
H&E    hematoxylin and eosin 
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HP    hyperforin 
HPex    hyperforin extract 
HPLC    high-performance liquid chromatography 
HRP    horseradish peroxidase 
HY    hypericin 
HYex    hypericin extract 
IAP    inhibitor of apoptosis proteins 
IFN    interferon 
IGF-1    insulin like growth factor-1  
IGF-IRα   insulin like growth factor-I-receptor-α 
IHC    immunohistochemistry 
IκB    inhibitor of NF-κB 
IKK    IκB kinase 
IL    interleukin 
iNOS    inducible nitric oxide synthase 
IR    insulin receptor 
JNK    c-Jun amino-terminal kinase 
LDL    low density lipoprotein  
LSD    least significant difference 
MAM    methylazoxymethanol 
MAPK    mitogen activated protein kinase 
MCH     mean corpuscular hemoglobin 
MCHC    mean corpuscular hemoglobin concentration  
MCV     mean corpuscular volume  
MTT                                            3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide  
NEMO                NF-κB essential modulator 
NIK    NF-κB-inducing kinase 
NF-κB    nuclear transcription factor-κB 
PARP    poly (ADP ribose) polymerase 
PMA    phorbol ester phorbol 12-myristate 13-acetate 
RAIDD    RIP associated Ich-1/CED with death domain 
RBC     red blood cell count  
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RDW    red cell distribution width    
RHD    Rel homology domain 
RIP    receptor interacting protein 
RNS    reactive nitrogen species 
ROS    reactive oxygen species 
SD    Sprague-Dawley rats 
SDc    Sprague-Dawley rats control group 
SDS-PAGE   Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
SJW    St. John’s Wort 
SODD    silencer of death domain 
TACE    TNF-α converting enzyme 
TB    total bilirubin 
TG    triglycerides 
TIL    tumor infiltrating lymphocyte 
TNBS    trinitrobenzene sulfonic acid 
TNF-α    tumor necrosis factor-α 
TNFR1    tumor necrosis factor receptor 1 
TNFR2    tumor necrosis factor receptor 2 
sTNFR1   soluble tumor necrosis factor receptor 1 
sTNFR2   soluble tumor necrosis factor receptor 2 
TRADD   TNF Receptor I associated death domain 
TRAF    TNF Receptor Associated factor 
TRAIL    TNF-related apoptosis-inducing ligand 
TRAMP   TNF receptor apoptosis-mediating protein 
WBC     white blood cell count  
Zk-Ln    Zucker lean rats 
Zk-Lnc    Zucker lean rats control group 
Zk-Ob    Zucker obese rats 




CBC and Plasma Test Descriptions 
CBC Analyses 
 
RBC: Red Blood Cell Count , number of red blood cells in a blood sample 
HCT: Percentage of red blood cells 
Hb:  Hemoglobin count, protein that picks up oxygen in the lungs and delivers it to the  
         peripheral tissues  
Platelets: involved in blood clotting 
RDW: Measures the range of sizes of red blood cells in a blood sample 
MCH: Hemoglobin amount per red blood cell  
MCV: Average red blood cell size  
MCHC: Hemoglobin concentration per red blood cell. 
WBC: White Blood Cell Count (leukocyte count). The number of white blood cells blood including    
neutrophils, band cells (slightly immature neutrophils), T-type lymphocytes, B-type 
lymphocytes, monocytes, eosinophils, and basophils.  
Segregated neutrophils: mature immune cells involved in phagocytosis 
Lymphocytes: involved in humoral and cellular immune responses, antibody production, antigen    
          presentation 
Monocytes:  involved in phagocytosis, antigen presentation 
















TG: storage form of fat consisting of three fatty acids and glycerol 
HDL: a lipoprotein that transports cholesterol in the blood. High levels of HDL, as opposed to LDL  
           are considered beneficial. 
Cholesterol: fatty steroid produced by the liver, involved in membrane fluidity and hormone  
                      formation 
Glucose: monosaccharide sugar, source of energy for the body 
CK: Creatinine kinase assay, high levels indicating stress to muscle, heart or brain 
ALT:  measures amount of alanine aminotransferase enzyme in the blood, high levels indicate liver  
           disease 
AST: measures amount of aspartate aminotransferase enzyme in the blood, high levels indicate liver  
          disease 

































Figure C3: Linear range western blots for β-actin for (A) cells, (B) colonic mucosa, and (C)  
tumors.   
Increasing amounts of protein from cell, mucosal, or tumor homogenates were loaded, separated by 
SDS-PAGE, and transferred on membranes. Following incubation with primary and secondary 
antibodies, membranes were exposed, and protein saturation points determined for subsequent 
analyses. 















































Figure C4: Western blots of β-actin protein expression in HT-29 cells treated with (A) TNF-α, 
and (B) TNF-α and SJW extracts and standards. 
HT-29 cells were treated with TNF-α and/or SJW, and processed for western blot analyses. Proteins 
were separated by SDS-PAGE and transferred onto membranes. Blots were then incubated with 
primary antibody for β-actin, followed by HRP conjugated secondary antibody, and exposed in 











Figure C5: Western blots of β-actin protein expression in colon mucosae of (A) control and (B) 
AOM injected Zk-Ob, Zk-Ln, and SD rats.  
Colonic mucosal proteins were separated by SDS-PAGE and transferred onto membranes. Blots were 
then incubated with primary antibody for β-actin, followed by AP conjugated secondary antibody, 





Figure C6: Western blots of β-actin protein expression in (A) Zk-Ob, Zk-Ln, and SD tumors, 
and (B) distal and proximal tumors from Zk-Ob rats.   
Tumor proteins were separated by SDS-PAGE and transferred onto membranes. Blots were then 
incubated with primary antibody for β-actin, followed by AP conjugated secondary antibody, and 





















Figure C7: Levels of (A) sTNFRI and (B) sTNFRII in tumors of Zk-Ob, Zk-Ln and SD rats. 
Samples were incubated in a 96 well plate pre-coated with antibody. Wells were then aspirated, 
washed, and further incubated with conjugated antibody. Reaction was monitored upon addition of 
substrate solution, and absorbance read at 450nm. Values are mean ± SE, n=6 tumors per group. Bars 
without a common superscript(x,y,z) are significantly different, p<0.05, as determined by ANOVA 















































                                 
 
Figure C8: Negative control for IHC analyses. Sections were analyzed as per described IHC 
protocol, with the exception of incubation with primary antibody. As seen, no reaction (brown 
colouring) is observed, ensuring specificity of the procedure.     
 
Table C1: Comparison of relative hypericin and hyperforin amounts in LD50 values of SJW 










aHY: hypericin, HYex: hypericin  extract, HP: hyperforin, HPex: hyperforin extract.   
 
 HPLC analyses of extracts confirmed total amount of active constituent of HY and HP present (data 
provided by University of Guelph). Relative amount of HY and HP constituents in both extracts were 
compared to amount of HY and HP in commercially available standards, using LD50 values from the 
MTT assay as a reference point. Unlike hyperforin, which was similar between extract and standard, 
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Table C2: Biochemical analyses of plasma samples collected from control and AOM injected 
Zk-Ob, Zk-Ln and SD animalsa. 
CK (U/L) 138.7±12.7x 302.3±78.6y 108.2±9.7x 228.3±25.4y 269.6±67.2y 123.4±16.9x 
ALT (U/L) 61.7±6.4xy 67.0±18.4xy 63.6±4.0xy 59.8±5.5x 53.5±4.1x 87.4±12.2y 
AST (U/L) 115.7±31.2x 196.3±19.1x 97.0±5.2x 133.7±14.9x 109.6±12.2x 142.7±31.7x 
CB (μmol/L) 0±0x 3.3±1.25y 0±0x 0±0x 0.63±0.2z 0.13±0.1z 
TB (μmol/L) 1.7±0.3x 4.8±1.0y 3±0.5xy 2.9±0.5x 3.1±0.6xy 4.4±0.3y 
aPlasma was isolated from heparinized blood samples collected at termination of 30 week old control 
and AOM injected Zk-Ob, Zk-Ln, and SD animals. Biochemical parameters were tested as indicated 
where CK: creatinine kinase, ALT: alanine aminotransferase, AST: aspartate aminotransferase, CB: 
conjugated bilirubin, TB: total bilirubin. Values expressed as mean ± SE, with at least n=8 per group. 
Values in a row without a common superscript (w,x,y,z) are significantly different, p<0.05, as 
determined by ANOVA analyses with LSD and Tukey post hoc tests. Overall Zk-Ob animals had 
higher levels of each parameter than Zk-Ln and SD rats. AOM: azoxymethane, Zk-Ob: Zucker obese, 
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